

08444790

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1649JXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 19 Jun 03 New e-mail delivery for search results now available
NEWS 20 Jun 10 MEDLINE Reload
NEWS 21 Jun 10 PCTFULL has been reloaded
NEWS 22 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 23 Jul 19 NTIS to be reloaded July 28, 2002
NEWS 24 Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 25 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 26 Jul 30 NETFIRST to be removed from STN

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:14:18 ON 31 JUL 2002

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:14:27 ON 31 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 30 JUL 2002 HIGHEST RN 441272-85-1
DICTIONARY FILE UPDATES: 30 JUL 2002 HIGHEST RN 441272-85-1

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s dsvcpqgkyihp/sqsp

L1 102 DSVCPQGKYIHP/SQSP

=> s dsvcpqgkyihpqxns/sqsp

L2 0 DSVCPQGKYIHPQXNS/SQSP

=> s dsvcpqgkyihpqx/sqsp

L3 0 DSVCPQGKYIHPQX/SQSP

=> s dsvcpqgkyihpq/sqsp

L4 101 DSVCPQGKYIHPQ/SQSP

=> dup rem l4

DUPLICATE IS NOT AVAILABLE IN 'REGISTRY'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4

L5 101 DUP REM L4 (0 DUPLICATES REMOVED)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	------------------	---------------

FILE 'CAPLUS' ENTERED AT 10:16:21 ON 31 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Jul 2002 VOL 137 ISS 5
FILE LAST UPDATED: 30 Jul 2002 (20020730/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 10:14:18 ON 31 JUL 2002)

FILE 'REGISTRY' ENTERED AT 10:14:27 ON 31 JUL 2002

L1 102 S DSVCPQGKYIHP/SQSP
L2 0 S DSVCPQGKYIHPQXNS/SQSP
L3 0 S DSVCPQGKYIHPQX/SQSP
L4 101 S DSVCPQGKYIHPQ/SQSP
L5 101 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'CAPLUS' ENTERED AT 10:16:21 ON 31 JUL 2002

=> s l4

L6 64 L4

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 64 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l7 and wallach

L8 64 S L7
697 WALLACH
L9 0 L8 AND WALLACH

=> s l7 and rubinstein

L10 64 S L7
144 RUBINSTEIN
L11 0 L10 AND RUBINSTEIN

=> s l7 and wallach/au

L12 64 S L7
1 WALLACH/AU
L13 0 L12 AND WALLACH/AU

=> s l7 and rubinstein/au

L14 64 S L7
2 RUBINSTEIN/AU
L15 0 L14 AND RUBINSTEIN/AU

=> d l7 ibib kwic

L7 ANSWER 1 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:391912 CAPLUS

DOCUMENT NUMBER: 137:1836

TITLE: Measurement of DNA methylation for analysis of the
toxicology of substances

INVENTOR(S): Olek, Alexander; Piepenbrock, Christian; Berlin, Kurt

PATENT ASSIGNEE(S): Epigenomics Ag, Germany

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040710	A2	20020523	WO 2001-EP12951	20011108
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10056802	A1	20020529	DE 2000-10056802	20001114
PRIORITY APPLN. INFO.:			DE 2000-10056802 A	20001114
IT 431544-32-0	431544-37-5, Protein (human gene PAI1)	431544-38-6, Protein (human gene A2M)	431544-39-7, Protein (human 207-amino acid)	
431544-40-0	431544-41-1, Alpha-1-antitrypsin (aa 268-394) (human)	431544-42-2, Protein (human 412-amino acid)	431544-43-3, Decoy receptor 3 (human gene DcR3)	431544-44-4
431544-45-5	431544-46-6, Protein (human clone hhm2 gene HMG-2)	431544-47-7, UEV-1 (human clone MAC4 gene UBE2V)	431544-48-8	431544-49-9
431544-50-2	431544-51-3	431544-52-4	431544-53-5	431544-54-6, Protein (human gene TOP1)
431544-55-7, Protein (human gene TOP2A)	431544-56-8, Protein (human 261-amino acid)	431544-57-9	431544-58-0	431544-59-1
431544-60-4, Protein (human gene DNTT)	431544-61-5	431544-62-6	431544-63-7	431544-64-8
431544-65-9, Excision repair protein (human)	431544-66-0	431544-67-1, Protein (human 732-amino acid)	431544-68-2, Protein (human gene ERCC3)	431544-69-3, Protein (human 609-amino acid)
431544-70-6	431544-71-7, Protein (human 152-amino acid)	431544-72-8	431544-73-9, Protein (human gene MGMT)	431544-74-0
431544-75-1	431544-76-2, Protein (human gene hmlh1)	431544-77-3, HHR23A protein (human gene HHR23A)	431544-78-4, DNA-PK (human)	431544-79-5
431544-80-8, RAD52 (human cell line Jurkat)	431544-81-9, Protein (human gene ATM)	431544-82-0, Rad50 (human gene Rad50)	431544-83-1	431544-84-2
431544-85-3, Protein (human gene hMSH2)	431544-86-4, HMSH6 protein (human gene MSH6)	431544-87-5	431544-88-6	431544-89-7, Protein (human gene hPMS1)
431544-90-0, Protein (human gene hPMS2)	431544-91-1, Protein (human gene LIG1)	431544-92-2, XPAC protein (human		

gene XPAC) 431544-93-3, XRCC4 (human) 431544-94-4 431544-95-5
 431544-96-6 431544-97-7 431544-98-8, Protein (human 304-amino acid)
 431544-99-9, Protein (human cell line C32 gene HAP1) 431545-00-5, AP
 endonuclease 1 (human gene HAP1) 431545-01-6, Protein (human gene
 RAD54)
 431545-02-7, HsRad51 (human gene HsRAD51) 431545-03-8, Protein (human
 gene RAG1) 431545-04-9 431545-05-0, DNase I (human clone 14C6 gene
 DNL1L) 431545-06-1 431545-07-2 431545-08-3, Cyclin D3 (human gene
 CCND3) 431545-09-4, Cyclin (human) 431545-10-7, D-type cyclin (human
 gene CCND2) 431545-11-8, Cyclin G1 (human) 431545-12-9, Cyclin K
 (human gene CPR4) 431545-13-0 431545-14-1 431545-15-2 431545-16-3
 431545-17-4 431545-18-5, Protein (human gene clk3) 431545-19-6
 431545-20-9, ERK5 (human clone 3-1) 431545-21-0, Protein (human
 297-amino acid) 431545-22-1 431545-23-2, Serine/threonine protein
 kinase (human) 431545-24-3 431545-25-4, PLK (human clone PL-5, PL-8,
 PL-PCR) 431545-26-5, Chk1 (human gene CHK1) 431545-27-6
 431545-28-7, HsGAK (human) 431545-29-8, Protein (human gene SATB1)
 431545-30-1 431545-31-2 431545-32-3, P14-CDK inhibitor (human)
 431545-33-4 431545-34-5 431545-35-6, Id-1H (human cell line TIG-3
 gene
 Id-1H) 431545-36-7, Protein (human gene PTMA) 431545-37-8
 431545-38-9 431545-39-0, Protein (human gene cdc25A) 431545-40-3,
 Protein (human gene cdc25B) 431545-41-4, Protein (human gene CDC25Hu2)
 431545-42-5, Protein (human 473-amino acid) 431545-43-6,
 Metallothionein-III (human) 431545-44-7, CDC37 (human) 431545-45-8
 431545-46-9, BTG2 (human gene BTG2) 431545-47-0, RCL (human gene Rcl)
 431545-48-1, HSP40 (human gene hsp40) 431545-49-2, Protein (human
 573-amino acid) 431545-50-5, Protein (human 312-amino acid)
 431545-51-6 431545-52-7, Heat shock protein (human gene HSPA1L)
 431545-53-8 431545-54-9, Protein (human gene HSPA1L) 431545-55-0
 431545-56-1, Heat shock protein (human gene HSPA2) 431545-57-2
 431545-58-3, Rhodanese (human clone Rho1.1) 431545-59-4, Cytosolic
 epoxide hydrolase (human) 431545-60-7, Serum paraoxonase (human gene
 PON) 431545-61-8, Protein (human 290-amino acid) 431545-62-9
 431545-63-0, Zeta-crystallin (human) 431545-64-1 431545-65-2
 431545-66-3, Protein (human gene CYP2B) 431545-67-4, Protein (human
 gene
 CYP2B) 431545-68-5, Cytochrome P450 (human gene CYP4A) 431545-69-6,
 Cholesterol 7-alpha-hydroxylase (human) 431545-70-9, Protein (human
 347-amino acid) 431545-71-0, Protein (human gene CYP2C) 431545-72-1,
 Protein (human gene CYP2C) 431545-73-2, Protein (human 370-amino acid)
 431545-74-3, Cytochrome (human gene CYP2C19) 431545-75-4, Protein
 (human
 493-amino acid) 431545-76-5, Protein (human gene CYP2F1) 431545-77-6,
 Protein (human 511-amino acid) 431545-78-7, Protein (human 515-amino
 acid) 431545-79-8 431545-80-1 431545-81-2 431545-82-3
 431545-83-4 431545-84-5, Protein (human 155-amino acid) 431545-85-6,
 Gst-pi protein (human) 431545-86-7, Glutathione peroxidase (human)
 431545-87-8 431545-88-9, Metallothionein (human) 431545-89-0
 431545-90-3, MT-11 protein (human clone pBlue-MT-11) 431545-91-4
 431545-92-5 431545-93-6, Heme oxygenase-2 (human) 431545-94-7
 431545-95-8 431545-96-9 431545-97-0, Protein (human 222-amino acid)
 431545-98-1, Glutathione synthetase (human) 431545-99-2 431546-00-8
 431546-01-9, Protein (human 233-amino acid) 431546-02-0 431546-03-1,
 Fas ligand (human) 431546-04-2 431546-05-3 **431546-06-4**,
 Protein (human 455-amino acid) 431546-07-5 431546-10-0 431546-11-1
 431546-12-2 431546-13-3, CD27BP (human cell line HeLa gene Siva)
 431546-14-4 431546-15-5, ICH-1L (human gene Ich-1) 431546-16-6,
 ICH-1S
 (human gene Ich-1) 431546-17-7 431546-18-8 431546-19-9
 431546-20-2
 431546-21-3 431546-22-4 431546-23-5 431546-24-6, Apo-2 ligand
 (human) 431546-25-7 431546-26-8, FADD-ous ICE/CED-3-like protease
 (human) 431546-27-9, MACH-alpha-1 (human) 431546-28-0 431546-29-1,
 Protein (human clone bcl-xL gene bcl-xL) 431546-30-4, Protein (human
 clone bcl-xS gene bcl-xS) 431546-31-5, Protein (human 239-amino acid)

431546-32-6 431546-33-7 431546-34-8 431546-37-1, BAG1 (human gene BAG1) 431546-38-2 431546-39-3, Protein (human 551-amino acid) 431546-40-6 431546-59-7, DAD-1 (human cell line Raji) 431546-60-0, Sulfated glycoprotein-2 (human gene CLI) 431546-61-1, Gadd153 (human gene GADD153) 431546-62-2, TLS-CHOP (human gene TLS/CHOP)

431546-63-3, Inhibitor of apoptosis protein 1 (human) 431546-64-4, MIHC (human gene MIHC) 431546-65-5 431546-71-3, Apoptosis inhibitor survivin (human) 431546-72-4, Sentrin (human) 431546-73-5, Anti-death protein (human gene IEX-1L) 431546-74-6, Protein (human gene PPOL) 431546-75-7, Protein (human gene PPOL) 431546-76-8, Protein (human 439-amino acid) 431546-77-9, Protein (human gene p53associated) 431546-78-0, Protein (human 241-amino acid) 431546-79-1, Protein (human gene TP53) 431546-80-4, Protein (human gene TP53) 431546-81-5 431546-82-6 431546-83-7, Protein (human gene JUN) 431546-84-8, Protein (human gene IGFBP1) 431546-85-9 431546-86-0, Protein (human gene ABL1) 431546-87-1, Protein (human clone RB-[1,5] gene RB1) 431546-88-2, L-myc protein (human) 431546-89-3, L-myc protein (human gene L-myc) 431546-90-6, BRCA2 (human gene BRCA2) 431546-91-7, Protein (human 271-amino acid) 431546-92-8, Nucleophosmin (human) 431546-93-9 431546-94-0, Protein (human 380-amino acid) 431546-95-1, Protein (human gene MET) 431546-96-2 431546-97-3, Stromelysin-3 precursor (human) 431546-98-4 431546-99-5, Protein (human gene c-Ha-ras-1) 431547-00-1, MMAC1 (human gene MMAC1)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; measurement of DNA methylation for anal. of the toxicol. of substances)

=> d his

(FILE 'HOME' ENTERED AT 10:14:18 ON 31 JUL 2002)

FILE 'REGISTRY' ENTERED AT 10:14:27 ON 31 JUL 2002

L1 102 S DSVCPQGKYIHP/SQSP
 L2 0 S DSVCPQGKYIHPQXNS/SQSP
 L3 0 S DSVCPQGKYIHPQX/SQSP
 L4 101 S DSVCPQGKYIHPQ/SQSP
 L5 101 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'CAPLUS' ENTERED AT 10:16:21 ON 31 JUL 2002

L6 64 S L4
 L7 64 DUP REM L6 (0 DUPLICATES REMOVED)
 L8 64 S L7
 L9 0 S L7 AND WALLACH
 L10 64 S L7
 L11 0 S L7 AND RUBINSTEIN
 L12 64 S L7
 L13 0 S L7 AND WALLACH/AU
 L14 64 S L7
 L15 0 S L7 AND RUBINSTEIN/AU

=> d ibib kwic hit 1-10

L15 HAS NO ANSWERS

'1-10 ' IS NOT A VALID SEARCH STATUS KEYWORD

Search status keywords:

NONE ---- Display only the number of postings.

STATUS -- Display statistics of the search.

ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ?:

ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ?:

ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ?:/

'/' IS NOT A VALID SEARCH STATUS KEYWORD

Search status keywords:

NONE ---- Display only the number of postings.

STATUS -- Display statistics of the search.

ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ??:?

Search status keywords

NONE ---- Display only the number of postings.

STATUS -- Display statistics of the search.

ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ?:none

L4 101 SEA FILE=REGISTRY ABB=ON PLU=ON DSVCPQGKYIHPQ/SQSP
L6 64 SEA FILE=CAPLUS ABB=ON PLU=ON L4
L7 64 DUP REM L6 (0 DUPLICATES REMOVED)
L14 64 SEA FILE=CAPLUS L7
L15 0 SEA FILE=CAPLUS ABB=ON PLU=ON L14 AND RUBINSTEIN/AU

=> d his

(FILE 'HOME' ENTERED AT 10:14:18 ON 31 JUL 2002)

FILE 'REGISTRY' ENTERED AT 10:14:27 ON 31 JUL 2002

L1 102 S DSVCPQGKYIHP/SQSP
L2 0 S DSVCPQGKYIHPQXNS/SQSP
L3 0 S DSVCPQGKYIHPQX/SQSP
L4 101 S DSVCPQGKYIHPQ/SQSP
L5 101 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'CAPLUS' ENTERED AT 10:16:21 ON 31 JUL 2002

L6 64 S L4
L7 64 DUP REM L6 (0 DUPLICATES REMOVED)
L8 64 S L7
L9 0 S L7 AND WALLACH
L10 64 S L7
L11 0 S L7 AND RUBINSTEIN
L12 64 S L7
L13 0 S L7 AND WALLACH/AU
L14 64 S L7
L15 0 S L7 AND RUBINSTEIN/AU

=> d l6 total ibib kwic

L6 ANSWER 1 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:488138 CAPLUS

DOCUMENT NUMBER: 137:57591

TITLE: Apoptosis inducing Molecule II and methods of use

INVENTOR(S): Ebner, Reinhard; Yu, Guo-liang; Ruben, Steven M.;
Zhang, Jun; Ullrich, Stephen; Zhai, Yifan

PATENT ASSIGNEE(S): Human Genome Sciences, USA

SOURCE: U.S. Pat. Appl. Publ., 96 pp., Cont.-in-part of U.S.
Ser. No. 27,287.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002081647	A1	20020627	US 1999-252656	19990219
US 2002064869	A1	20020530	US 1998-27287	19980220

PRIORITY APPLN. INFO.:

US 1996-13923P P 19960322
 US 1996-30157P P 19961031
 US 1997-822953 B2 19970321
 US 1998-3886 B2 19980107
 US 1998-27287 A2 19980220
 US 1998-75409P P 19980220

IT 439540-91-7 439540-92-8 439541-15-8 439620-16-3

RL: PRP (Properties)

(unclaimed protein sequence; apoptosis inducing Mol. II and methods of use)

L6 ANSWER 2 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:409195 CAPLUS

DOCUMENT NUMBER: 137:1567

TITLE: Human apoptosis inducing molecule II and its cDNA and use thereof in drug screening and therapy

INVENTOR(S): Ebner, Reinhard; Yu, Guo-liang; Ruben, Steven M.; Ullrich, Stephen

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 79 pp., Cont.-in-part of U.S. Ser. No. 822,953, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002064869	A1	20020530	US 1998-27287	19980220
CA 2317057	AA	19990715	CA 1999-2317057	19990107
WO 9935262	A2	19990715	WO 1999-US242	19990107
WO 9935262	A3	19991202		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9921063	A1	19990726	AU 1999-21063	19990107
EP 1044270	A2	20001018	EP 1999-901341	19990107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002500043	T2	20020108	JP 2000-527646	19990107
CA 2321186	AA	19990826	CA 1999-2321186	19990219
WO 9942584	A1	19990826	WO 1999-US3703	19990219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9929721	A1	19990906	AU 1999-29721	19990219
EP 1054968	A1	20001129	EP 1999-910970	19990219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002504333	T2	20020212	JP 2000-532524	19990219
US 2002081647	A1	20020627	US 1999-252656	19990219
PRIORITY APPLN. INFO.:				
			US 1996-13923P	P 19960322
			US 1996-30157P	P 19961031

US 1997-822953 B2 19970321
 US 1998-3886 A 19980107
 US 1998-27287 A 19980220
 US 1998-75409P P 19980220
 WO 1999-US242 W 19990107
 WO 1999-US3703 W 19990219

IT 433280-13-8 433280-14-9 433280-15-0 433280-16-1
 433280-45-6

RL: PRP (Properties)

(unclaimed protein sequence; human apoptosis inducing mol. II and its
 cDNA and use thereof in drug screening and therapy)

L6 ANSWER 3 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:391912 CAPLUS

DOCUMENT NUMBER: 137:1836

TITLE: Measurement of DNA methylation for analysis of the
 toxicology of substances

INVENTOR(S): Olek, Alexander; Piepenbrock, Christian; Berlin, Kurt

PATENT ASSIGNEE(S): Epigenomics Ag, Germany

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040710	A2	20020523	WO 2001-EP12951	20011108
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,				
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056802	A1	20020529	DE 2000-10056802	20001114
PRIORITY APPLN. INFO.:			DE 2000-10056802 A	20001114
IT 431544-32-0		431544-37-5, Protein (human gene PAI1)	431544-38-6,	
Protein (human gene A2M)		431544-39-7, Protein (human 207-amino acid)		
431544-40-0		431544-41-1, Alpha-1-antitrypsin (aa 268-394) (human)		
431544-42-2, Protein (human 412-amino acid)		431544-43-3, Decoy receptor		
3 (human gene Dcr3)		431544-44-4	431544-45-5	431544-46-6, Protein
(human clone hmg2 gene HMG-2)		431544-47-7, UEV-1 (human clone MAC4		
gene				
UBE2V)		431544-48-8	431544-49-9	431544-50-2
431544-51-3				
431544-52-4		431544-53-5	431544-54-6, Protein (human gene TOP1)	
431544-55-7, Protein (human gene TOP2A)		431544-56-8, Protein (human		
261-amino acid)		431544-57-9	431544-58-0	431544-59-1
431544-60-4,				
Protein (human gene DNTT)		431544-61-5	431544-62-6	431544-63-7
431544-64-8		431544-65-9, Excision repair protein (human)	431544-66-0	
431544-67-1, Protein (human 732-amino acid)		431544-68-2, Protein (human		
gene ERCC3)		431544-69-3, Protein (human 609-amino acid)	431544-70-6	
431544-71-7, Protein (human 152-amino acid)		431544-72-8	431544-73-9,	
Protein (human gene MGMT)		431544-74-0	431544-75-1	431544-76-2,
Protein (human gene hmlh1)		431544-77-3, HHR23A protein (human gene		
HHR23A)		431544-78-4, DNA-PK (human)	431544-79-5	431544-80-8, RAD52
(human cell line Jurkat)		431544-81-9, Protein (human gene ATM)		
431544-82-0, Rad50 (human gene Rad50)		431544-83-1	431544-84-2	
431544-85-3, Protein (human gene hMSH2)		431544-86-4, HMSH6 protein		
(human gene MSH6)		431544-87-5	431544-88-6	431544-89-7, Protein
(human gene hPMS1)		431544-90-0, Protein (human gene hPMS2)		
431544-91-1, Protein (human gene LIG1)		431544-92-2, XPAC protein (human		
gene XPAC)		431544-93-3, XRCC4 (human)	431544-94-4	431544-95-5

431544-96-6 431544-97-7 431544-98-8, Protein (human 304-amino acid)
 431544-99-9, Protein (human cell line C32 gene HAP1) 431545-00-5, AP
 endonuclease 1 (human gene HAP1) 431545-01-6, Protein (human gene
 RAD54)
 431545-02-7, HsRad51 (human gene HsRAD51) 431545-03-8, Protein (human
 gene RAG1) 431545-04-9 431545-05-0, DNase I (human clone 14C6 gene
 DNL1L) 431545-06-1 431545-07-2 431545-08-3, Cyclin D3 (human gene
 CCND3) 431545-09-4, Cyclin (human) 431545-10-7, D-type cyclin (human
 gene CCND2) 431545-11-8, Cyclin G1 (human) 431545-12-9, Cyclin K
 (human gene CPR4) 431545-13-0 431545-14-1 431545-15-2 431545-16-3
 431545-17-4 431545-18-5, Protein (human gene clk3) 431545-19-6
 431545-20-9, ERK5 (human clone 3-1) 431545-21-0, Protein (human
 297-amino acid) 431545-22-1 431545-23-2, Serine/threonine protein
 kinase (human) 431545-24-3 431545-25-4, PLK (human clone PL-5, PL-8,
 PL-PCR) 431545-26-5, Chk1 (human gene CHK1) 431545-27-6
 431545-28-7, HsGAK (human) 431545-29-8, Protein (human gene SATB1)
 431545-30-1 431545-31-2 431545-32-3, P14-CDK inhibitor (human)
 431545-33-4 431545-34-5 431545-35-6, Id-1H (human cell line TIG-3
 gene
 Id-1H) 431545-36-7, Protein (human gene PTMA) 431545-37-8
 431545-38-9 431545-39-0, Protein (human gene cdc25A) 431545-40-3,
 Protein (human gene cdc25B) 431545-41-4, Protein (human gene CDC25Hu2)
 431545-42-5, Protein (human 473-amino acid) 431545-43-6,
 Metallothionein-III (human) 431545-44-7, CDC37 (human) 431545-45-8
 431545-46-9, BTG2 (human gene BTG2) 431545-47-0, RCL (human gene Rcl)
 431545-48-1, HSP40 (human gene hsp40) 431545-49-2, Protein (human
 573-amino acid) 431545-50-5, Protein (human 312-amino acid)
 431545-51-6 431545-52-7, Heat shock protein (human gene HSPA1L)
 431545-53-8 431545-54-9, Protein (human gene HSPA1L) 431545-55-0
 431545-56-1, Heat shock protein (human gene HSPA2) 431545-57-2
 431545-58-3, Rhodanese (human clone Rho1.1) 431545-59-4, Cytosolic
 epoxide hydrolase (human) 431545-60-7, Serum paraoxonase (human gene
 PON) 431545-61-8, Protein (human 290-amino acid) 431545-62-9
 431545-63-0, Zeta-crystallin (human) 431545-64-1 431545-65-2
 431545-66-3, Protein (human gene CYP2B) 431545-67-4, Protein (human
 gene
 CYP2B) 431545-68-5, Cytochrome P450 (human gene CYP4A) 431545-69-6,
 Cholesterol 7-alpha-hydroxylase (human) 431545-70-9, Protein (human
 347-amino acid) 431545-71-0, Protein (human gene CYP2C) 431545-72-1,
 Protein (human gene CYP2C) 431545-73-2, Protein (human 370-amino acid)
 431545-74-3, Cytochrome (human gene CYP2C19) 431545-75-4, Protein
 (human
 493-amino acid) 431545-76-5, Protein (human gene CYP2F1) 431545-77-6,
 Protein (human 511-amino acid) 431545-78-7, Protein (human 515-amino
 acid) 431545-79-8 431545-80-1 431545-81-2 431545-82-3
 431545-83-4 431545-84-5, Protein (human 155-amino acid) 431545-85-6,
 Gst-pi protein (human) 431545-86-7, Glutathione peroxidase (human)
 431545-87-8 431545-88-9, Metallothionein (human) 431545-89-0
 431545-90-3, MT-1l protein (human clone pBlue-MT-1l) 431545-91-4
 431545-92-5 431545-93-6, Heme oxygenase-2 (human) 431545-94-7
 431545-95-8 431545-96-9 431545-97-0, Protein (human 222-amino acid)
 431545-98-1, Glutathione synthetase (human) 431545-99-2 431546-00-8
 431546-01-9, Protein (human 233-amino acid) 431546-02-0 431546-03-1,
 Fas ligand (human) 431546-04-2 431546-05-3 **431546-06-4**,
 Protein (human 455-amino acid) 431546-07-5 431546-10-0 431546-11-1
 431546-12-2 431546-13-3, CD27BP (human cell line HeLa gene Siva)
 431546-14-4 431546-15-5, ICH-1L (human gene Ich-1) 431546-16-6,
 ICH-1S
 (human gene Ich-1) 431546-17-7 431546-18-8 431546-19-9
 431546-20-2
 431546-21-3 431546-22-4 431546-23-5 431546-24-6, Apo-2 ligand
 (human) 431546-25-7 431546-26-8, FADD-ous ICE/CED-3-like protease
 (human) 431546-27-9, MACH-alpha-1 (human) 431546-28-0 431546-29-1,
 Protein (human clone bcl-xL gene bcl-xL) 431546-30-4, Protein (human
 clone bcl-xS gene bcl-xS) 431546-31-5, Protein (human 239-amino acid)
 431546-32-6 431546-33-7 431546-34-8 431546-37-1, BAG1 (human gene

BAG1) 431546-38-2 431546-39-3, Protein (human 551-amino acid)
 431546-40-6 431546-59-7, DAD-1 (human cell line Raji) 431546-60-0,
 Sulfated glycoprotein-2 (human gene CLI) 431546-61-1, Gadd153 (human
 gene GADD153) 431546-62-2, TLS-CHOP (human gene TLS/CHOP)
 431546-63-3,
 Inhibitor of apoptosis protein 1 (human) 431546-64-4, MIHC (human gene
 MIHC) 431546-65-5 431546-71-3, Apoptosis inhibitor survivin (human)
 431546-72-4, Sentrin (human) 431546-73-5, Anti-death protein (human
 gene
 IEX-1L) 431546-74-6, Protein (human gene PPOL) 431546-75-7, Protein
 (human gene PPOL) 431546-76-8, Protein (human 439-amino acid)
 431546-77-9, Protein (human gene p53associated) 431546-78-0, Protein
 (human 241-amino acid) 431546-79-1, Protein (human gene TP53)
 431546-80-4, Protein (human gene TP53) 431546-81-5 431546-82-6
 431546-83-7, Protein (human gene JUN) 431546-84-8, Protein (human gene
 IGFBP1) 431546-85-9 431546-86-0, Protein (human gene ABL1)
 431546-87-1, Protein (human clone RB-[1,5] gene RB1) 431546-88-2, L-myc
 protein (human) 431546-89-3, L-myc protein (human gene L-myc)
 431546-90-6, BRCA2 (human gene BRCA2) 431546-91-7, Protein (human
 271-amino acid) 431546-92-8, Nucleophosmin (human) 431546-93-9
 431546-94-0, Protein (human 380-amino acid) 431546-95-1, Protein (human
 gene MET) 431546-96-2 431546-97-3, Stromelysin-3 precursor (human)
 431546-98-4 431546-99-5, Protein (human gene c-Ha-ras-1) 431547-00-1,
 MMAC1 (human gene MMAC1)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; measurement of DNA methylation for anal. of the
 toxicol. of substances)

L6 ANSWER 4 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:353306 CAPLUS

DOCUMENT NUMBER: 136:350562

TITLE: Use of IL-1 inhibitors and TNF antagonists, partially
 in combination with recombinant erythropoietins, for
 the treatment of anemia

INVENTOR(S): Kay, Jonathan; McCabe, Dorothy; Newmark, Richard;
 Coccia, Marco A.

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036152	A1	20020510	WO 2001-US46205	20011030
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002077294	A1	20020620	US 2001-969739	20011002
PRIORITY APPLN. INFO.:			US 2000-244792P P	20001031
			US 2001-969739 A	20011002
REFERENCE COUNT:	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE		

FORMAT

IT 330988-75-5, STNF-RI

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(sTNF-RI; use of IL-1 inhibitors and TNF antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia)

IT 7439-89-6, Iron, biological studies 11096-26-7, Erythropoietin 113427-24-0, Epoetin alfa 143090-92-0, Anakinra 170277-31-3, Infliximab 185243-69-0, Etanercept 199685-57-9, Onercept 209810-58-2, Darbepoetin alfa 339184-10-0, CDP 870
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of IL-1 inhibitors and TNF antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia)

L6 ANSWER 5 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:335528 CAPLUS
DOCUMENT NUMBER: 136:395580
TITLE: Safety, pharmacokinetics and pharmacodynamics of recombinant human tumor necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers
AUTHOR(S): Trinchard-Lugan, I.; Ho-Nguyen, Q.; Bilham, W. M.; Buraglio, M.; Ythier, A.; Munafo, A.
CORPORATE SOURCE: Serono International S.A., Geneva, 1228, Switz.
SOURCE: European Cytokine Network (2001), 12(3), 391-398
CODEN: ECYNEJ; ISSN: 1148-5493
PUBLISHER: John Libbey Eurotext
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 199685-57-9, Onercept
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(pharmacol. study of recombinant human tumor necrosis factor-binding protein-1 (Onercept) injected by i.v., i.m. and s.c. routes into healthy volunteers)

L6 ANSWER 6 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:271976 CAPLUS
DOCUMENT NUMBER: 136:274360
TITLE: Osteoprotegerin in treatment of osteoporosis and other bone diseases
INVENTOR(S): Boyle, William J.; Lacey, David L.; Calzone, Frank J.;
Chang, Ming-Shi
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S., 117 pp., Cont. of U.S. Ser. No. 577,788.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6369027	B1	20020409	US 1996-706945	19960903
DE 19654610	A1	19970626	DE 1996-19654610	19961220
FR 2742767	A1	19970627	FR 1996-15707	19961220
FR 2742767	B1	20010330		
CA 2210467	AA	19970703	CA 1996-2210467	19961220
WO 9723614	A1	19970703	WO 1996-US20621	19961220

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
DE 10045592 A1 20020328 DE 2000-10045592 20000915
PRIORITY APPLN. INFO.: DE 2000-10045592 A 20000915
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 405181-14-8, Selectokine W24 (synthetic human) 405181-16-0,
Selectokine W33 (synthetic human)
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study);
USES

(Uses)

(amino acid sequence; antibody-cytokine-cytokine inhibitor fusion
protein (selectokine) for use as target-specific prodrug)

L6 ANSWER 8 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:172124 CAPLUS

DOCUMENT NUMBER: 136:231252

TITLE: Tumor necrosis factor receptors 6.alpha. and 6.beta.
for diagnosing/treating immune disorders and

screening

agonists and antagonists

INVENTOR(S): Gentz, Reiner L.; Ebner, Reinhard; Yu, Guo-liang;
Ruben, Steven M.; Ni, Jian; Feng, Ping

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA

SOURCE: PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018622	A2	20020307	WO 2001-US26396	20010824
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2000-227598P	P 20000825
			US 2000-252131P	P 20001121
			US 2001-303224P	P 20010706

IT 403572-28-1 403572-29-2 403572-30-5 403572-31-6
403572-32-7 403572-33-8 403572-34-9 403572-35-0 403572-36-1
403572-37-2 403572-38-3 403572-39-4

RL: PRP (Properties)

(unclaimed protein sequence; tumor necrosis factor receptors 6.alpha.
and 6.beta. for diagnosing/treating immune disorders and screening
agonists and antagonists)

L6 ANSWER 9 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:72748 CAPLUS

DOCUMENT NUMBER: 136:146104

TITLE: Human stress genes identified using DNA microarrays

INVENTOR(S): Chenchik, Alex; Lukashev, Matvey E.

PATENT ASSIGNEE(S): Clontech, USA

SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S.
Ser. No. 441,920.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002009730	A1	20020124	US 2001-782909	20010213
PRIORITY APPLN. INFO.:			US 1998-222256	B2 19981228
			US 1999-440305	B2 19991117
			US 1999-441920	A2 19991117
IT			391973-18-5, Signalosome subunit 2 (human gene SGN2)	391973-19-6
			391973-20-9, Protein (human 375-amino acid)	391973-21-0 391973-22-1
			391973-23-2, 23 KD highly basic protein (human)	391973-24-3, Ribosomal protein S9 (human)
			391973-25-4, Protein (human 685-amino acid)	
			391973-26-5, Phospholipase A2 (human)	391973-27-6, Protein (human 218-amino acid)
			391973-28-7 391973-29-8 391973-30-1, TAXREB67 protein (human)	391973-31-2, Protein (human 241-amino acid)
			391973-32-3, Protein (human 455-amino acid)	391973-33-4, HGF activator precursor (human)
			391973-34-5, Protein (human 271-amino acid)	
			391973-35-6 391973-36-7, Recombinant glial growth factor (human)	
			391973-37-8 391973-38-9, Protein (human 91-amino acid)	391973-39-0
			391973-40-3, Protein (human 252-amino acid)	391973-41-4, Protein (human gene IL4)
			391973-42-5 391973-43-6 391973-44-7, Protein (human 233-amino acid)	391973-45-8 391973-46-9 391973-47-0 391973-48-1
			391973-49-2 391973-50-5 391973-51-6 391973-52-7 391973-53-8, Protein (human gene CSF2)	391973-54-9, Integrin alpha subunit (human)
			391973-55-0 391973-56-1, Protein (human gene ICAM1)	391973-57-2, Protein (human gene TGFB3)
			391973-58-3 391973-59-4 391973-60-7	
			391973-61-8 391973-62-9 391973-63-0, Protein (human gene PAI1)	
			391973-64-1, GTP-binding protein (human gene RAB5)	391973-65-2, Protein (human 1207-amino acid)
			391973-66-3 391973-67-4, Protein (human 135-amino acid)	391973-68-5 391973-69-6 391973-70-9 391973-71-0
			391973-72-1 391973-73-2, Amphiphysin (human clone 22-2)	391973-74-3
			391973-75-4, Interleukin-2 (human)	391973-76-5, 5-HT1D-type serotonin receptor (human)
			391973-77-6 391973-78-7 391973-79-8, Protein (human 1049-amino acid)	391973-80-1 391973-81-2, Fas ligand (human)
			391973-82-3, L-myc protein (human)	391973-83-4, L-myc protein (human gene L-myc)
			391973-84-5, I-Rel (human cell line Jurkat)	391973-85-6, Protein (human 271-amino acid)
			391973-86-7 391973-87-8, Protein (human 239-amino acid)	391973-88-9, Apo-2 ligand (human)
			391973-89-0	
			391973-90-3, Protein (human gene cdc25B)	391973-91-4, Protein (human gene CDC25Hu2)
			391973-92-5, P14-CDK inhibitor (human)	391973-93-6
			391973-94-7 391973-95-8, Protein (human 187-amino acid)	391973-96-9, Protein (human 313-amino acid)
			391973-97-0 391973-98-1 391973-99-2	
			391974-00-8 391974-01-9 391974-02-0, Protein (human gene TK2)	
			391974-03-1 391974-04-2, MT-MMP (human)	391974-05-3, MT-MMP (human gene human29)
			391974-06-4, Cadherin-6 (human cell line C-Li21)	
			391974-07-5, Cadherin-11 (human)	391974-08-6, Cadherin-12 (human)
			391974-09-7, Br-cadherin (human clone 8B1)	391974-10-0, Cadherin-13 (human)
			391974-11-1 391974-12-2, Serine/threonine protein kinase (human)	391974-13-3 391974-14-4 391974-15-5, CD27BP (human cell line HeLa gene Siva)
			391974-16-6, Apoptosis inhibitor survivin (human)	
			391974-17-7 391974-18-8, PLK (human clone PL-5, PL-8, PL-PCR)	
			391974-19-9, Protein (human gene MET)	391974-20-2, CDC37 (human)
			391974-21-3, Protein (human 207-amino acid)	391974-22-4 391974-23-5, Stromelysin-3 precursor (human)
			391974-24-6 391974-25-7	
391974-26-8,				
			Calmegin (human)	391974-27-9 391974-28-0, Protein (human gene MAD3)
			391974-29-1 391974-30-4, UEV-1 (human clone MAC4 gene UBE2V)	
			391974-31-5 391974-32-6, Mad protein (human gene hMAD-2)	391974-33-7
			391974-34-8, FUSE binding protein 2 (human gene FBP2)	391974-35-9, BTG2 (human gene BTG2)
			391974-36-0, Sentrin (human)	391974-37-1, Protein (human 334-amino acid)
			391974-38-2 391974-39-3 391974-40-6, Metallothionein (human)	391974-41-7 391974-42-8, MT-11 protein (human clone pBlue-MT-11)
			391974-43-9 391974-44-0, Chk1 (human gene CHK1)	

391974-45-1, Protein (human 193-amino acid) 391974-46-2, AP-4 (human gene AP-4) 391974-47-3, Fatty acid synthase (human) 391974-48-4, Protein (human gene c-Ha-ras-1) 391974-49-5, Ornithine decarboxylase (ODC) (human) 391974-50-8, Protein (human clone hhmg2 gene HMG-2) 391974-51-9 391974-52-0, RCL (human gene Rcl) 391974-53-1 391974-54-2, Cyclin K (human gene CPR4) 391974-55-3, Anti-death protein (human gene IEX-1L) 391974-56-4, PAP ous protein (human) 391974-57-5 391974-58-6, Rhodanese (human clone Rho1.1) 391974-59-7, HsGAK (human) 391974-60-0 391974-61-1 391974-62-2 391974-63-3, Neuromedin B (human gene NMB) 391974-64-4, Protein (human 1480-amino acid) 391974-65-5 391974-66-6 391974-67-7, Alpha-1-antitrypsin (aa 268-394) (human) 391974-68-8 391974-69-9 391974-70-2 391974-71-3 391974-72-4 391974-73-5 391974-74-6 391974-75-7, Protein (human 100-amino acid) 391974-76-8, Pre-apolipoprotein CIII (human) 391974-77-9, Protein (human 499-amino acid) 391974-78-0, Cytochrome P450 reductase (human) 391974-79-1, Protein (human 184-amino acid) 391974-80-4, Protein (human gene TIMP) 391974-81-5 391974-82-6 391974-83-7 391974-84-8 391974-85-9 391974-86-0, Protein (human 375-amino acid) 391974-87-1, Cholesterol esterase (human gene LIPA) 391974-88-2, Protein (human gene ALDH1) 391974-89-3, Precursor peptide (human) 391974-90-6, Protein (human 328-amino acid) 391974-91-7, Protein (human gene FABP2) 391974-92-8, Protein (human gene FABP1) 391974-93-9, Protein (human gene CBG) 391974-94-0 391974-95-1 391974-96-2, Fibrinogen gamma chain (human) 391974-97-3, Protein (human 169-amino acid) 391974-98-4, Protein (human 153-amino acid) 391974-99-5, Endothelin-converting-enzyme 1 (human) 391975-00-1 391975-01-2 391975-02-3 391975-03-4, VLACD (human strain Caucasoid) 391975-04-5, FIC1 (human) 391975-05-6 391975-06-7 391975-07-8 391975-08-9 391975-09-0, Protein (human 504-amino acid) 391975-10-3, Protein (human 503-amino acid) 391975-11-4, Protein (human 502-amino acid) 391975-12-5, Protein (human 503-amino acid) 391975-13-6 391975-14-7, Cholesterol 7-alpha-hydroxylase (human) 391975-15-8, Protein (human gene CYP17) 391975-16-9, Protein (human 424-amino acid) 391975-17-0 391975-18-1, Cyclooxygenase-2 (human gene Cox-2) 391975-19-2, Protein (human gene HMGCR) 391975-20-5, Protein (human gene PRNP) 391975-21-6, Protein (human gene LPL) 391975-22-7, Phospholipase (human) 391975-23-8 391975-24-9, Protein (human gene LBP) 391975-25-0 391975-26-1 391975-27-2, Pxaaalp (human gene PXAAA1) 391975-28-3, MMAC1 (human gene MMAC1) 391975-29-4 391975-30-7, Protein (human 347-amino acid) 391975-31-8 391975-32-9 391975-33-0, Protein (human 515-amino acid) 391975-34-1 391975-35-2, Protein (human 802-amino acid) 391975-36-3 391975-37-4, Connexin 40 (human) 391975-38-5, Involucrin (human gene IVL) 391975-39-6 391975-40-9, Protein (human 283-amino acid) 391975-41-0 391975-42-1, OCTN1 (human gene OCTN1) 391975-43-2 391975-44-3 391975-45-4 391975-46-5 391975-47-6 391975-48-7 391975-49-8 391975-50-1 391975-51-2, Alanine aminotransferase (human) 391975-52-3, VEGF-D (human) 391975-53-4, Protein (human gene ANT1) 391975-54-5, Protein (human gene DRA) 391975-55-6, Sulfonylurea receptor (human gene SUR1)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (amino acid sequence; human stress genes identified using DNA microarrays)

L6 ANSWER 10 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:833646 CAPLUS

DOCUMENT NUMBER: 135:366708

TITLE: Methods of identifying the activity of gene products

INVENTOR(S): Blume, Arthur J.; Goldstein, Neil; Pillutla, Renuka; Hsiao, Ku-Chuan; Prendergast, John

PATENT ASSIGNEE(S): DGI Biotechnologies, Inc., USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001086297	A2	20011115	WO 2001-US15092	20010509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-202912P P 20000509	
IT 135686-06-5	373386-49-3	373386-50-6	373386-51-7	373386-52-8
373386-53-9	373386-54-0	373386-55-1	373386-56-2	373386-57-3
373386-58-4	373442-93-4	373442-94-5	373442-95-6	
373442-96-7	373442-97-8	373442-98-9	373442-99-0	373443-00-6
373443-01-7	373601-45-7	373601-46-8	373601-47-9	373601-51-5
373601-54-8	373601-56-0	373601-57-1	373601-59-3	373601-60-6
373601-62-8	373601-64-0	373601-70-8	373601-79-7	373601-80-0
373601-81-1	373609-47-3			
RL: PRP (Properties) (unclaimed sequence; methods of identifying the activity of gene products)				

L6 ANSWER 11 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:833368 CAPLUS
DOCUMENT NUMBER: 135:370651
TITLE: Receptor from TNF family
INVENTOR(S): Boyle, William J.; Hsu, Hailing
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085782	A2	20011115	WO 2001-US4568	20010212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-181800P P 20000211	
IT 374541-17-0	374541-19-2	374579-06-3	374579-07-4	374579-08-5
374595-78-5	374595-79-6	374612-27-8		
RL: PRP (Properties) (unclaimed sequence; receptor from TNF family)				

L6 ANSWER 12 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:829001 CAPLUS
DOCUMENT NUMBER: 135:367227
TITLE: Methods of use for osteoprotegerin-binding protein

INVENTOR(S): receptors
 Boyle, William J.
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: U.S., 59 pp., Cont.-in-part of U.S. Ser. No. 880,855.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6316408	B1	20011113	US 1998-52521	19980330
US 5843678	A	19981201	US 1997-842842	19970416
WO 9846751	A1	19981022	WO 1998-US7584	19980415
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9871205	A1	19981111	AU 1998-71205	19980415
AU 743257	B2	20020124		
EP 975754	A1	20000202	EP 1998-918244	19980415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9808545	A	20000523	BR 1998-8545	19980415
JP 2001526532	T2	20011218	JP 1998-544257	19980415
ZA 9803189	A	19981016	ZA 1998-3189	19980416
NO 9905044	A	19991215	NO 1999-5044	19991015
PRIORITY APPLN. INFO.:			US 1997-842842	A2 19970416
			US 1997-880855	A2 19970623
			US 1998-52521	A 19980330
			WO 1998-US7584	W 19980415
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE		

FORMAT

IT 9002-64-6, Parathyroid hormone 62031-54-3, Fgf 163611-40-3,
 Tumor necrosis factor .alpha. inhibitor
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (osteoprotegerin-binding protein receptors for therapeutic use)

L6 ANSWER 13 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:716275 CAPLUS
 DOCUMENT NUMBER: 136:32045
 TITLE: Prostaglandin E1 reduces myocardial reperfusion injury
 by inhibiting proinflammatory cytokines production during cardiac surgery
 AUTHOR(S): Kawamura, Takae; Nara, Noriko; Kadosaki, Mamoru; Inada, Katsuya; Endo, Shigeatu
 CORPORATE SOURCE: Department of Anesthesiology, School of Medicine, Iwate Medical University, Iwate, 020-8505, Japan
 SOURCE: Critical Care Medicine (2000), 28(7), 2201-2208
 CODEN: CCMDC7; ISSN: 0090-3493
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 330988-75-5, STNF-RI

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prostaglandin E1 reduces myocardial reperfusion injury by inhibiting
proinflammatory cytokines prodn. during cardiac surgery in humans)

L6 ANSWER 14 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:716264 CAPLUS

DOCUMENT NUMBER: 136:36128

TITLE: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

AUTHOR(S): Abraham, Edward; Laterre, Pierre-Francois; Garbino, Jorge; Pingleton, Susan; Butler, Thomas; Dugernier, Thierry; Margolis, Benjamin; Kudsk, Kenneth;

Zimmerli,

Werner; Anderson, Paula; Reynaert, Marc; Lew, Daniel; Lesslauer, Werner; Passe, Sharon; Cooper, Philip; Burdeska, Alex; Modi, Marlene; Leighton, Anton;

Salgo,

Miklos; Van der Auwera, Philippe; McIntyre, R.; Reynaert, M.; Laterre, P.-F.; Lew, D.; Garbino, J.; Suter, P.; Pittei, D.; Romand, J.-A.; Ricou, B.; Mathey, B.; Pugin, J.; Chevrolet, J. C.; Dayer, J.

M.;

Pingleton, S.; Butler, T.; Dugernier, T.; Honore, P.; Margolis, B.; Kudsk, K.; Zimmerli, W.; Trampuz, A.; Anderson, P.; Belmont, D.; Smith, D.; Postier, R.; Brackett, D.; Teres, D.; Lafleur, K.; Zeni, P.; Viallon, A.; Venet, C.; Bruining, H. A.; Leon, A.; Lepouse, C.; Pannacciulli, E.; Beffagna, B.; Gasparini, L.; Niguarda, Ospedale; Reina, D.;

Kaufman,

D.; Haas, C.; Demongeon, G.; Piralla, R.; Installe, E.; Gonzalez, M.; Dive, A. M.; Evrard, P.; Kljucar, S.; Heimesaat, M.; Lambot, D.; Tobin, E.; Sheehan,

A.;

Rogovein, T. S.; Zijlstra, J. G.; Tulleken, J. E.; Rumbak, M.; Haupt, M.; Thill, M.; Huyghens, L.; Spapen, H.; Diltor, M.; Wilson, M.; Burch, J.;

Riker,

R.; Kovitz, K.; Multx, A.; Anderson, C. L.; Carranza, S.; Cote, C.; Daniel, S.; Baughman, R.; Berman, S.

J.;

Johnson, E. W.; Cohen, J.; Lynn, W. A.; Kieft, H.; Meyer, R. P.; Keizer, E. H. D.; Malledant, Y.;

Seguin,

P.; Chambers, H.; Taeuber, M.; Zanetti, G.; Lodato, R.; Schippers, S.; Michael, J.; Liou, T.; Samuelson, W.; Zirngibl, H.; Dogan, N.; Dolgner, D.; O'Neill,

P.;

Vincent, J.-L.; Silva, E.; Murray, M.; De Ruyter, M. L.; Harrison, B. A.; Peters, J. L.; Polkow, M.; Berman, S. J.; Dreyfuss, D.; Farkas, S.; Gottlieb,

J.;

Mittelkoetter, U.; Parrish, J.; Bernardin, G.;

Carlet,

J.; Dhainaut, J.-F.; Marin, N.; Gariou, A.; Kelly,

K.;

Levy, H.; Locay, H.; Audrain, D.; Strange, C.; Carlson, R.; Kearl, R.; Ferro, T.; Nelson, N.; Hudes, C.; Fletcher, E.; Friedman, H.; Herchline, T.; Kirby, A.; Motsch, J.; Grube, C.; Kalenka, A.; Offenstadt, G.; Maury, E.; Pinsard, M.; Rothe, K. F.; Kunstle,

T.;

Russel, J.; Speelberg, B.; Thompson, D.; O'Maeghan, R.; Fisher, C.; Halpern, N.; Pastores, S. M.; Alicea,

M.; Weilemann, L.; Brower, R.; Dofferhoff, A.; de Meyer, A.; Kvetan, V.; Liebler, J.; Pourriat, J. L.; Gauzit, R.; Baud, M.; Samii, K.; Smithies, M.; Evans, G.; Light, B.; Mcleod, P.; Otto, C.; Silverman, . H.; Shanholtz, C.; Williams, K.; Ralk, R.; Brase, R.; Vogt, A.; Paul, W.; Burchardi, H.; Fein, A.; Kelly, J.; Martin, C.; Minei, J.; Nichols, D.; Scheld, W.

M.;

Schneider, F.; Torri, G.; Giudici, D.; Welte, T.; Wong, D.

CORPORATE SOURCE: Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO, 80262, USA

SOURCE: Critical Care Medicine (2001), 29(3), 503-510
CODEN: CCMDC7; ISSN: 0090-3493

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 156679-34-4, Lenercept

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological

study); USES (Uses)

(p55 tumor necrosis factor receptor fusion protein lenercept effect on mortality in humans with severe sepsis and early septic shock)

L6 ANSWER 15 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:145198 CAPLUS

DOCUMENT NUMBER: 134:188974

TITLE: DNA encoding human hybrid heterodimeric proteins for modulation of protein-protein interactions

INVENTOR(S): Campbell, Robert K.; Jameson, Bradford A.; Chappel, Scott C.

PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth. Antilles

SOURCE: U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 804,166.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6194177	B1	20010227	US 1997-910991	19970814
US 6193972	B1	20010227	US 1997-804166	19970220
US 2001014333	A1	20010816	US 2001-756186	20010109
PRIORITY APPLN. INFO.:			US 1996-11936P	P 19960220
			US 1997-804166	A2 19970220

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 195460-68-5P 195460-70-9P 195460-72-1P

195460-74-3P

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (amino acid sequence; of human hybrid heterodimeric proteins for modulation of protein-protein interactions)

L6 ANSWER 16 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:50502 CAPLUS
 DOCUMENT NUMBER: 134:126521
 TITLE: Combination therapy for conditions leading to bone loss using osteoprotegerins
 INVENTOR(S): Boyle, William J.; Lacey, David Lee; Calzone, Frank J.; Chang, Ming-Shi; Senaldi, Giorgio
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 316 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001003719	A2	20010118	WO 2000-US18667	20000707
WO 2001003719	A3	20020221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-350670	A 19990709
			US 1999-457647	A 19991209
IT 321456-78-4	321456-80-8	321456-81-9	321456-83-1	
321456-84-2	321456-85-3	321456-86-4	321456-87-5	321456-88-6
321573-93-7				
RL: PRP (Properties) (unclaimed protein sequence; combination therapy for conditions leading to bone loss using osteoprotegerins)				

L6 ANSWER 17 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:12289 CAPLUS
 DOCUMENT NUMBER: 134:80816
 TITLE: Combination of tumors necrosis factor (TNF) antagonists and cyclooxygenase 2 (COX-2) inhibitors for the treatment of inflammation
 INVENTOR(S): Keane, J. Timothy
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000229	A1	20010104	WO 2000-US16292	20000626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1189628	A1	20020327	EP 2000-944668	20000626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:

US 1999-141238P P 19990624

WO 2000-US16292 W 20000626

OTHER SOURCE(S): MARPAT 134:80816

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 61413-54-5 83373-60-8, D-609 111025-83-3, Vinigrol 142130-73-2,
MDL-201112 151101-39-2 **156679-34-4**, Lenercept 162011-90-7
166798-78-3, BB-2275 169590-42-5 170277-31-3, Infliximab
170569-86-5
180200-68-4 181695-72-7 185243-69-0, Etanercept 189940-24-7
198470-84-7 **199685-57-9**, Onercept 202409-33-4 212126-32-4
226072-63-5, Solimastat 316149-01-6 316350-82-0, PCM 4 316350-99-9,
AGT 1 316351-02-7, CytoTAB
RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES

(Uses)

(TNF antagonist-COX-2 inhibitor combination for inflammation treatment)

L6 ANSWER 18 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:842003 CAPLUS

DOCUMENT NUMBER: 134:4058

TITLE: Human tumor necrosis factor receptor 5 and its coding cDNA sequence

INVENTOR(S): Wei, Ying-Fei; Ruben, Steven M.; Gentz, Reiner L.; Ni,

Jian

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA

SOURCE: PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071150	A1	20001130	WO 2000-US13515	20000518
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1191940	A1	20020403	EP 2000-932514	20000518
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1999-135164P P 19990520

WO 2000-US13515 W 20000518

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 106441-96-7 125723-33-3, Antigen CDw 40 (human precursor protein moiety reduced) **129203-92-5** 133655-57-9 141961-30-0, Antigen CD 27 (human PBMC cell precursor protein moiety reduced) 142193-23-5, Antigen Fas (human clone pF58 precursor reduced) 146705-43-3, Antigen CD 30 (human clone CD30-5 precursor reduced) 151217-01-5, Protein (smallpox virus strain India-1967 gene G4R reduced) 159036-51-8 161446-09-9,

RL: PRP (Properties)

(unclaimed protein sequence; human tumor necrosis factor receptor 5
and
its coding cDNA sequence)

L6 ANSWER 19 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:814344 CAPLUS

DOCUMENT NUMBER: 134:9335

TITLE: Death domain-containing receptor 4 for treating
immune

disorders and cancers
INVENTOR(S): Ni, Jian; Rosen, Craig A.; Pan, James G.; Gentz,
Reiner L.; Dixit, Vishva M.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; The Regents of the
University of Michigan

SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067793	A1	20001116	WO 2000-US12163	20000505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1178828	A1	20020213	EP 2000-932061	20000505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1999-132922P	P 19990506
			WO 2000-US12163	W 20000505
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE		

FORMAT

IT 129203-92-5 142193-23-5, Antigen Fas (human clone pF58 precursor
reduced) 184050-64-4

RL: PRP (Properties)

(unclaimed protein sequence; death domain-contg. receptor 4 for
treating immune disorders and cancers)

L6 ANSWER 20 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:790340 CAPLUS

DOCUMENT NUMBER: 133:355211

TITLE: Death domain-contg. receptor 5 and compns. for
treatment of immunity-related diseases, viral
diseases, and cancer

INVENTOR(S): Ni, Jian; Gentz, Reiner L.; Yu, Guo-liang; Rosen,
Craig A.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA

SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2000066156 A1 20001109 WO 2000-US12041 20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1196191 A1 20020417 EP 2000-930329 20000504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
US 2002072091 A1 20020613 US 2001-874138 20010606
PRIORITY APPLN. INFO.: US 1999-132498P P 19990504
US 1999-133238P P 19990507
US 1999-148939P P 19990813
US 1997-40846P P 19970317
US 1997-54021P P 19970729
US 1998-42583 A1 19980317
US 2000-565009 A1 20000504
WO 2000-US12041 W 20000504
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 129203-92-5 142193-23-5, Antigen Fas (human clone pF58 precursor
reduced) 184050-64-4
RL: PRP (Properties)
(unclaimed protein sequence; death domain-contg. receptor 5 and
compns.
for treatment of immunity-related diseases, viral diseases, and
cancer)

L6 ANSWER 21 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:772482 CAPLUS
DOCUMENT NUMBER: 133:340202
TITLE: Compositions containing tetracyclines for treating
hemorrhagic virus infections and other disorders
INVENTOR(S): Fredeking, Terry M.; Ignatyev, George M.
PATENT ASSIGNEE(S): Antibody Systems, Inc., USA
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064479	A1	20001102	WO 2000-US11700	20000426
W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1171163	A1	20020116	EP 2000-928635	20000426
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
US 2002077276	A1	20020620	US 2001-840707	20010423
PRIORITY APPLN. INFO.:			US 1999-198210P P 19990427 US 1999-301274 A1 19990427	

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 94948-10-4, Lymphotoxin (human precursor protein moiety) 94948-60-4,
Tumor necrosis factor (human precursor reduced) 95471-82-2, Interleukin
1 (human clone pcD-415 precursor protein moiety reduced) 97599-23-0,
Interleukin 1.alpha. (human clone p10A precursor reduced) 124541-29-3
128559-29-5, Interleukin 1 receptor antagonist (human clone IL-1ra-2a
isoform precursor protein moiety reduced) **129203-92-5**
133655-57-9 142106-89-6 178304-43-3 178304-45-5 178304-49-9
178304-51-3 186208-08-2 186208-10-6 186208-12-8 186208-13-9,
Calpain (human)
RL: PRP (Properties)
(unclaimed protein sequence; compns. contg. tetracyclines for treating
hemorrhagic virus infections and other disorders)

L6 ANSWER 22 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:772469 CAPLUS

DOCUMENT NUMBER: 133:329582

TITLE: Antibodies to death domain-containing receptors DR3
and DR3-V1 for immune system disorders and cancer
INVENTOR(S): Yu, Guo-liang; Ni, Jian; Gentz, Reiner L.; Dillon,
Patrick J.; Dixit, Vishva M.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; The Regents of the
University of Michigan

SOURCE: PCT Int. Appl., 273 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064465	A1	20001102	WO 2000-US10741	20000421
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,				
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,				
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1178815	A1	20020213	EP 2000-926218	20000421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1999-130488P	P 19990422
			US 1999-136741P	P 19990528
			WO 2000-US10741	W 20000421

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT **129203-92-5** 303170-97-0 303170-99-2

RL: PRP (Properties)

(unclaimed protein sequence; antibodies to death domain-contg.
receptors DR3 and DR3-V1 for immune system disorders and cancer)

L6 ANSWER 23 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:688346 CAPLUS

DOCUMENT NUMBER: 133:262311

TITLE: Human tumor necrosis factor receptor TR9 and TR9 cDNA

INVENTOR(S): Ni, Jian; Gentz, Reiner L.; Yu, Guo-liang; Fan, Ping

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA

SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056862	A1	20000928	WO 2000-US6831	20000316
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1171579	A1	20020116	EP 2000-914975	20000316
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6358508	B1	20020319	US 2000-527236	20000316
PRIORITY APPLN. INFO.:			US 1999-126019P P 19990324	
			US 1999-134220P P 19990514	
			US 1997-52991P P 19970611	
			US 1998-95094 A2 19980610	
			WO 2000-US6831 W 20000316	

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 129203-92-5 296966-49-9 296966-50-2 296966-59-1
296966-60-4 297164-67-1 297164-68-2 297164-69-3 297164-70-6
297164-71-7
RL: PRP (Properties)
(unclaimed protein sequence; human tumor necrosis factor receptor TR9 and TR9 cDNA)

L6 ANSWER 24 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:645884 CAPLUS
DOCUMENT NUMBER: 133:242574
TITLE: Apoptosis-inducing molecule II and for antitumor, antiarthritic, antiautoimmune, and other therapeutic use
INVENTOR(S): Ebner, Reinhard; Yu, Guo-liang; Ruben, Steven M.; Zhai, Yifan; Ullrich, Stephen
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 388 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053223	A1	20000914	WO 2000-US6332	20000310
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

EP 1161261 A1 20011212 EP 2000-914913 20000310
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 PRIORITY APPLN. INFO.: US 1999-124041P P 19990311
 US 1999-137457P P 19990604
 US 1999-142657P P 19990706
 US 1999-148326P P 19990811
 US 1999-168380P P 19991202
 WO 2000-US6332 W 20000310
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 94948-10-4, Lymphotoxin (human precursor protein moiety)
 129203-92-5 159994-84-0, Fas ligand (human) 203211-54-5
 210227-94-4 292886-55-6 292886-66-9 292886-67-0 292886-68-1
 292886-69-2 292886-70-5 292886-71-6 292886-72-7 293307-32-1
 RL: PRP (Properties)
 (unclaimed protein sequence; apoptosis-inducing mol. II and for
 antitumor, antiarthritic, antiautoimmune, and other therapeutic use)

L6 ANSWER 25 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:628154 CAPLUS
 DOCUMENT NUMBER: 133:236828
 TITLE: Tumor necrosis factor receptors 6.alpha. and 6.beta.
 INVENTOR(S): Gentz, Reiner L.; Ni, Jian; Ebner, Reinhard; Yu,
 Guo-liang; Ruben, Steven M.; Feng, Ping
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: PCT Int. Appl., 332 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052028	A1	20000908	WO 2000-US5686	20000303
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1159286	A1	20011205	EP 2000-916071	20000303
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1999-121774P P 19990304
 US 1999-124092P P 19990312
 US 1999-131279P P 19990427
 US 1999-131964P P 19990430
 US 1999-146371P P 19990802
 US 1999-168235P P 19991201
 WO 2000-US5686 W 20000303
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 106441-96-7 125723-33-3, Antigen CDw 40 (human precursor protein moiety reduced) 129203-92-5 133655-57-9 141961-30-0, Antigen CD 27 (human PBMC cell precursor protein moiety reduced) 142193-23-5, Antigen Fas (human clone pF58 precursor reduced) 146705-43-3, Antigen CD 30 (human clone CD30-5 precursor reduced) 151217-01-5, Protein (smallpox virus strain India-1967 gene G4R reduced) 159036-51-8 161446-09-9, Receptor 4-1BB (human precursor) 166025-61-2 171237-69-7

RL: PRP (Properties)
(unclaimed protein sequence; tumor necrosis factor receptors 6.alpha.
and 6.beta.)

L6 ANSWER 26 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:608760 CAPLUS
DOCUMENT NUMBER: 133:188463
TITLE: Single nucleotide polymorphisms in the human tumor
necrosis factor receptor gene and sequence variants
of
the receptor
INVENTOR(S): Nandabalan, Krishnan; Schulz, Vincent P.; Stephens,
J.
PATENT ASSIGNEE(S): Claiborne; Chew, Anne
Genaissance Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050436	A1	20000831	WO 2000-US4606	20000223
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-121314P P 19990223	
REFERENCE COUNT: 5			THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE	

FORMAT

IT 129203-92-5D, amino acid variants
RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
PRP
(Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; single nucleotide polymorphisms in human tumor
necrosis factor receptor gene and sequence variants of receptor)

L6 ANSWER 27 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:401875 CAPLUS
DOCUMENT NUMBER: 133:54564
TITLE: Sequences and characterization of the anti-apoptotic
protein encoded by human cytomegalovirus UL144 ORF
INVENTOR(S): Leong, Clement; Phillips, Joseph H.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034335	A2	20000615	WO 1999-US26035	19991203
WO 2000034335	A3	20000810		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO,				

NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
 UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 1998-205018 A 19981204
 IT 129203-92-5 134773-87-8 142193-23-5, Antigen Fas (human clone
 pF58 precursor reduced) 189704-47-0 197665-71-7 198917-33-8
 202220-47-1 202834-38-6 213474-05-6
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
 (Properties); BIOL (Biological study); PROC (Process)
 (amino acid sequence; sequences and characterization of anti-apoptotic
 protein encoded by human cytomegalovirus UL144 ORF)

L6 ANSWER 28 OF 64 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:257933 CAPLUS
 DOCUMENT NUMBER: 133:29472
 TITLE: No increased insulin sensitivity after a single
 intravenous administration of a recombinant human
 tumor necrosis factor receptor: Fc fusion protein in
 obese insulin-resistant patients
 AUTHOR(S): Paquot, Nicolas; Castillo, Manuel J.; Lefebvre,
 Pierre
 J.; Scheen, Andre J.
 CORPORATE SOURCE: Division of Diabetes, Nutrition, and Metabolic
 Disorders, Department of Medicine, C.H.U.
 Sart-Tilman,
 Liege, B-4000, Belg.
 SOURCE: Journal of Clinical Endocrinology and Metabolism
 (2000), 85(3), 1316-1319
 CODEN: JCEMAZ; ISSN: 0021-972X
 PUBLISHER: Endocrine Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR
 THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT
 IT 156679-34-4, Ro 45-2081
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES
 (Uses)
 (insulin sensitivity after a single i.v. administration of a
 recombinant human tumor necrosis factor receptor-Fc fusion protein in
 obese insulin-resistant patients)

L6 ANSWER 29 OF 64 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:573096 CAPLUS
 DOCUMENT NUMBER: 131:194124
 TITLE: TNF neutralization in MS: results of a randomized,
 placebo-controlled multicenter study
 AUTHOR(S): Arnason, B. G. W.; Jacobs, G.; Hanlon, M.; Harding
 Clay, B.; Noronha, A. B. C.; Auty, A.; Davis, B.;
 Nath, A.; Bouchard, J. P.; Belanger, C.; Gosselin,
 F.;
 Thibault, M.; Duquette, P.; Bourgoin, P.; DuBois, R.;
 Girard, M.; Ebers, G. C.; Rice, G. P. A.;
 Vandervoort,
 M. K.; Francis, G. S.; Duncan, L.; Lapierre, Y.;
 Freedman, M. S.; Christie, S. N.; Rabinovitch, H. E.;
 Metz, L. M.; Patry, D.; Murphy, W. F.; Peters, S.;
 McGuinness, S. D.; Murray, T. J.; Bhan, V.; Maxner, C.
 E.; Van Dorpe, R.; Oger, J. J.; Nelson, J.; Morrison,
 W.; Bogle, N.; Beall, S.; Vorobeychick, G.;

Hiltbrunner, A. Valerie; Bock, J.; Habil, Dr.;
Lesslauer, W.; Paty, D. W.; Li, D. K. B.; Zhao,

G.-J.;

Murray, T. J.

CORPORATE SOURCE:
The

The Lenercept Multiple Sclerosis Study Group, USA;

SOURCE:

University of British Columbia MS/MRI Analysis Group
Neurology (1999), 53(3), 457-465

PUBLISHER:

CODEN: NEURAI; ISSN: 0028-3878

DOCUMENT TYPE:

Lippincott Williams & Wilkins

LANGUAGE:

Journal

REFERENCE COUNT:

English

THIS

29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 156679-34-4, Lenercept

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(lenercept treatment in humans with multiple sclerosis)

L6 ANSWER 30 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:485358 CAPLUS

DOCUMENT NUMBER: 131:114891

TITLE:

Immunological inhibitors of tumor necrosis factor -
.alpha. (a review)

AUTHOR(S):

Tang, Hailan

CORPORATE SOURCE:

Coll. of Med., Jinan Univ., Canton, 510362, Peop.

Rep.

China

SOURCE:

Jinan Daxue Xuebao, Ziran Kexue Yu Yixueban (1998),
19(2), 89-91

CODEN: JDXUET; ISSN: 1000-9965

PUBLISHER:

Jinan Daxue Xuebao Bianjibu

DOCUMENT TYPE:

Journal; General Review

LANGUAGE:

Chinese

IT 163611-40-3, Tumor necrosis factor .alpha. inhibitor

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(immunol. inhibitors of tumor necrosis factor - .alpha.)

L6 ANSWER 31 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:397448 CAPLUS

DOCUMENT NUMBER: 131:212732

TITLE:

Cytokines, anti-cytokines and acute pancreatitis

AUTHOR(S):

Sargen, K.; Kingsnorth, A. N.

CORPORATE SOURCE:

Department of Surgery, Postgraduate Medical School,
Plymouth, UK

SOURCE:

EOS--Rivista di Immunologia ed Immunofarmacologia
(1999), 19(1), 23-27

CODEN: EOSSDJ; ISSN: 0392-6699

PUBLISHER:

Sigma-Tau s.p.a

DOCUMENT TYPE:

Journal; General Review

LANGUAGE:

English

REFERENCE COUNT:

62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR

THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 163611-40-3, Tumor necrosis factor .alpha. inhibitor

RL: BAC (Biological activity or effector, except adverse); BPR
(Biological

process); BSU (Biological study, unclassified); BIOL (Biological study);

PROC (Process)

(cytokines and cytokine inhibitors in acute pancreatitis)

L6 ANSWER 32 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:55952 CAPLUS

DOCUMENT NUMBER: 130:266010
TITLE: Neutralizing antibodies and receptor constructs
AUTHOR(S): Abraham, Edward
CORPORATE SOURCE: Division of Pulmonary Sciences and Critical Care
Medicine, University of Colorado Health Sciences
Center, Denver, CO, 80262, USA
SOURCE: Cytokines in Severe Sepsis and Septic Shock (1999),
285-293. Editor(s): Redl, Heinz; Schlag, Guenther.
Birkhaeuser: Basel, Switz.
CODEN: 67FMAG
DOCUMENT TYPE: Conference; General Review
LANGUAGE: English
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 156679-34-4, Lenercept
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic efficacy in human sepsis of)

L6 ANSWER 33 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:41856 CAPLUS
DOCUMENT NUMBER: 130:221928
TITLE: Animal pharmacokinetics of the tumor necrosis factor
receptor-immunoglobulin fusion protein Lenercept and
their extrapolation to humans
AUTHOR(S): Richter, Wolfgang F.; Gallati, Harald; Schiller,
Claus-Dieter
CORPORATE SOURCE: Pharma Division, Preclinical Research, F. Hoffmann-La
Roche Ltd., Basel, CH-4070, Switz.
SOURCE: Drug Metabolism and Disposition (1999), 27(1), 21-25
CODEN: DMDSAI; ISSN: 0090-9556
PUBLISHER: American Society for Pharmacology and Experimental
Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 156679-34-4, Lenercept
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(pharmacokinetics in lab. animals of)

L6 ANSWER 34 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:799848 CAPLUS
DOCUMENT NUMBER: 130:100653
TITLE: Eye drops containing amido compound as cytokine
inhibitor for treating eye diseases
INVENTOR(S): Mochizuki, Satoru; Sagawa, Kimitaka; Taguchi,
Hiroaki;
Okumura, Atsushi
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan; Toyobo Co.,
Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10330257	A2	19981215	JP 1997-143915	19970602
IT 123548-56-1	163611-40-3			

163611-40-3, Tumor necrosis factor-.alpha. inhibitor

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(eye drops contg. amido compd. as cytokine inhibitor for treating eye diseases)

L6 ANSWER 35 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:728561 CAPLUS
DOCUMENT NUMBER: 130:506
TITLE: Fusion proteins of osteoprotegerin dimerization domains and members of the tumor necrosis factor receptor family
INVENTOR(S): Boyle, William J.; Wooden, Scott
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9849305	A1	19981105	WO 1998-US8631	19980429
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874699	A1	19981124	AU 1998-74699	19980429
EP 980432	A1	20000223	EP 1998-922072	19980429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002514079	T2	20020514	JP 1998-547330	19980429
ZA 9803656	A	19981102	ZA 1998-3656	19980430
PRIORITY APPLN. INFO.:			US 1997-850188 A	19970501
			WO 1998-US8631 W	19980429
REFERENCE COUNT:	5		THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE	

FORMAT

IT 215665-02-4P 215665-05-7P 215665-08-0P

215665-15-9P 215665-16-0P

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; fusion proteins of osteoprotegerin dimerization domains and members of TNF receptor family)

IT 133723-60-1DP, fusion products with osteoprotegerin

135686-07-6DP, fusion products with osteoprotegerin

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; fusion proteins of osteoprotegerin dimerization domains and members of TNF receptor family)

IT 215665-03-5

RL: PRP (Properties)

(amino acid sequence; fusion proteins of osteoprotegerin dimerization domains and members of TNF receptor family)

L6 ANSWER 36 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:436948 CAPLUS
DOCUMENT NUMBER: 129:212201
TITLE: Cloning of soluble human tumor necrosis factor receptor I cDNA and its expression in prokaryotic and

AUTHOR(S): eukaryotic cells
 Mei, Xiu; Zhu, Chen; Dai, Weillie; Wang, Shunyou;
 Zhao,
 CORPORATE SOURCE: Shouyuan; Li, Changben
 State Key Laboratory of Genetic Engineering, Fudan
 University, Shanghai, Peop. Rep. China
 SOURCE: Fudan Xuebao, Ziran Kexueban (1998), 37(2), 129-134
 CODEN: FHPTAY; ISSN: 0427-7104
 PUBLISHER: Shanghai Kexue Jishu Chubanshe
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

IT 212252-62-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; cloning of sol. human tumor necrosis factor
 receptor I cDNA and its expression in prokaryotic and eukaryotic
 cells)

L6 ANSWER 37 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:394230 CAPLUS
 DOCUMENT NUMBER: 129:49649
 TITLE: Combination therapy using a TNF-binding protein for
 treating TNF-mediated diseases
 INVENTOR(S): Bendele, Alison M.; Sennello, Regina M.; Edwards,
 Carl
 K.
 PATENT ASSIGNEE(S): Amgen Inc., USA; Bendele, Alison M.; Sennello, Regina
 M.; Edwards, Carl K.
 SOURCE: PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824463	A2	19980611	WO 1997-US22733	19971208
W:				
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,				
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,				
US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
GN, ML, MR, NE, SN, TD, TG				
AU 9856961	A1	19980629	AU 1998-56961	19971208
EP 942740	A2	19990922	EP 1997-953156	19971208
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO				
JP 2001513754	T2	20010904	JP 1998-525893	19971208
US 6306820	B1	20011023	US 1999-326394	19990604
PRIORITY APPLN. INFO.:			US 1996-32587P	P 19961206
			US 1997-36355P	P 19970123
			US 1997-39315P	P 19970207
			US 1997-52023P	P 19970709
			WO 1997-US22733	W 19971208

IT 133723-60-1P 135686-07-6P

RL: BAC (Biological activity or effector, except adverse); BOC
 (Biological
 occurrence); BPN (Biosynthetic preparation); BSU (Biological study,
 unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological
 study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
 (amino acid sequence; combination therapy using a TNF-binding protein
 for treating TNF-mediated diseases)

ACCESSION NUMBER: 1998:65993 CAPLUS
 DOCUMENT NUMBER: 128:139767
 TITLE: Truncated soluble tumor necrosis factor type-I and type-II receptors
 INVENTOR(S): Fisher, Eric F.; Edwards, Carl K.; Kieft, Gary L.
 PATENT ASSIGNEE(S): Amgen Inc., USA; Fisher, Eric F.; Edwards, Carl K.; Kieft, Gary L.
 SOURCE: PCT Int. Appl., 206 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9801555	A2	19980115	WO 1997-US12244	19970709
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9706024	A	19980203	ZA 1997-6024	19970707
CA 2259156	AA	19980115	CA 1997-2259156	19970709
AU 9736013	A1	19980202	AU 1997-36013	19970709
EP 914431	A2	19990512	EP 1997-932603	19970709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9710350	A	19990817	BR 1997-10350	19970709
CN 1240479	A	20000105	CN 1997-197728	19970709
JP 2002514048	T2	20020514	JP 1998-505369	19970709
NO 9900086	A	19990309	NO 1999-86	19990108
PRIORITY APPLN. INFO.:			US 1996-21443P	P 19960709
			US 1996-32534P	P 19961206
			US 1997-37737P	P 19970123
			US 1997-39314P	P 19970207
			US 1997-39792P	P 19970304
			WO 1997-US12244	W 19970709

OTHER SOURCE(S): MARPAT 128:139767
 IT 133723-60-1DP, N- and C-terminal truncated derivs.
 133723-60-1P 135686-07-6DP, N- and C-terminal truncated derivs.
 202220-12-0P 202220-14-2P 202220-15-3DP, N- and C-terminal extended derivs. 202220-15-3P 202220-16-4P
 202220-17-5P 202220-18-6P 202220-19-7P 202220-20-0DP, N- and C-terminal extended derivs.
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; truncated sol. tumor necrosis factor type-I and type-II receptors)

ACCESSION NUMBER: 1998:56145 CAPLUS
 DOCUMENT NUMBER: 128:110576
 TITLE: Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways
 AUTHOR(S): Renzetti, L. M.; Gater, P. R.
 CORPORATE SOURCE: Hoffmann-LaRoche Inc., Nutley, NJ, 07110, USA
 SOURCE: Inflammation Research (1997), 46(Suppl. 2), S143-S144
 CODEN: INREFB; ISSN: 1023-3830
 PUBLISHER: Birkhaeuser Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English

IT 156679-34-4, Ro 45-2081
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(Ro 45-2081 prevents inflammatory responses in the airways)

L6 ANSWER 40 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:47304 CAPLUS
DOCUMENT NUMBER: 128:175964
TITLE: Ro 45-2081, a TNF receptor fusion protein, prevents
inflammatory responses in the airways
AUTHOR(S): Gater, P. R.; Renzetti, L. M.
CORPORATE SOURCE: Hoffmann-La Roche Inc., Nutley, NJ, 07042, USA
SOURCE: Agents and Actions Supplements (1998), 49(Therapeutic
Strategies for Modulating the Inflammatory Diseases),
67-71
CODEN: AASUDJ; ISSN: 0379-0363
PUBLISHER: Birkhaeuser Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 156679-34-4, Ro 45-2081
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(Ro 45-2081, TNF receptor fusion protein, prevents inflammatory
responses in airways)

L6 ANSWER 41 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:720483 CAPLUS
DOCUMENT NUMBER: 128:33556
TITLE: Determination of Tumor Necrosis Factor Binding
Protein
Disulfide Structure: Deviation of the Fourth Domain
Structure from the TNFR/NGFR Family Cysteine-Rich
Region Signature
AUTHOR(S): Jones, Michael D.; Hunt, John; Liu, Jennifer L.;
Patterson, Scott D.; Kohno, Tadahiko; Lu, Hsieng S.
CORPORATE SOURCE: Department of Protein Structure, Amgen Inc. Amgen
Center, Thousand Oaks, CA, 91320, USA
SOURCE: Biochemistry (1997), 36(48), 14914-14923
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 199685-57-9 199685-58-0
RL: PRP (Properties)
(amino acid sequence; detn. of tumor necrosis factor binding protein
disulfide structure and deviation of fourth domain structure from
TNFR/NGFR family cysteine-rich region signature)

L6 ANSWER 42 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:568294 CAPLUS
DOCUMENT NUMBER: 127:244008
TITLE: Recombinant fusion proteins comprising ligand-binding
receptor fragment linked with hormone subunit,
heterodimer formation, and pharmaceutical uses
INVENTOR(S): Campbell, Robert K.; Jameson, Bradford A.; Chappel,
Scott C.
PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth.
Antilles; Campbell, Robert K.; Jameson, Bradford A.;
Chappel, Scott C.
SOURCE: PCT Int. Appl., 60 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730161	A1	19970821	WO 1997-US2315	19970220
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2245877	AA	19970821	CA 1997-2245877	19970220
AU 9721252	A1	19970902	AU 1997-21252	19970220
AU 706504	B2	19990617		
EP 894141	A1	19990203	EP 1997-906604	19970220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1212017	A	19990324	CN 1997-192411	19970220
BR 9707589	A	20000104	BR 1997-7589	19970220
JP 2000504586	T2	20000418	JP 1997-529498	19970220
NO 9803799	A	19981019	NO 1998-3799	19980819
PRIORITY APPLN. INFO.:			US 1996-11936P	P 19960220
			WO 1997-US2315	W 19970220

IT 195460-68-5P 195460-70-9P 195460-72-1P
195460-74-3P
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; recombinant fusion proteins comprising ligand-binding receptor fragment linked with hormone subunit, heterodimer formation, and pharmaceutical uses)

L6 ANSWER 43 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:7431 CAPLUS
DOCUMENT NUMBER: 126:54622
TITLE: An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
AUTHOR(S): Huizinga, Tom W. J.; Dijkmans, Ben A. C.; van der Velde, Edo A.; van de Pouw Kraan, Tineke C. T. M.; Verweij, Cornelis L.; Breedveld, Ferdinand C.
CORPORATE SOURCE: Dep. Rheumatol., Univ. Hosp., Leiden, 2300 RC, Neth.
SOURCE: Annals of the Rheumatic Diseases (1996), 55(11), 833-836
CODEN: ARDIAO; ISSN: 0003-4967
PUBLISHER: BMJ Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 163611-40-3, Tumor necrosis factor .alpha. inhibitor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pentoxifylline and thalidomide as adjuvant therapy in the treatment of
rheumatoid arthritis in humans)

L6 ANSWER 44 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:89190 CAPLUS
DOCUMENT NUMBER: 124:127113
TITLE: Extraction and purification of tumor necrosis factor inhibitor from human urine

INVENTOR(S): Kajiwara, Junichi; Asada, Aki; Kiriwara, Kyoshi;
Kato,
Kazuo
PATENT ASSIGNEE(S): Japan Chem Res, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 07278192	A2	19951024	JP 1994-87436	19940401
IT	133723-60-1P				
	RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (extn. and purifn. of tumor necrosis factor inhibitor from human urine)				

L6 ANSWER 45 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:806446 CAPLUS
DOCUMENT NUMBER: 123:191813
TITLE: Molecules influencing the shedding of the tumor necrosis factor receptor, their preparation with recombinant cells, and their pharmaceutical use
INVENTOR(S): Wallach, David; Brakebusch, Cord; Varfolomeev, Eugene;
Batkin, Michael
PATENT ASSIGNEE(S): Israel
SOURCE: Can. Pat. Appl., 39 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	CA 2133872	AA	19950413	CA 1994-2133872	19941007
	AU 9475742	A1	19950504	AU 1994-75742	19941011
	AU 679559	B2	19970703		
	EP 657536	A1	19950614	EP 1994-116018	19941011
	EP 657536	B1	20010718		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 203273	E	20010815	AT 1994-116018	19941011
	ES 2163418	T3	20020201	ES 1994-116018	19941011
	JP 07194376	A2	19950801	JP 1994-274532	19941012
	ZA 9407962	A	19951121	ZA 1994-7962	19941012
	US 5665859	A	19970909	US 1994-321668	19941012
	US 5766917	A	19980616	US 1997-837941	19970428
PRIORITY APPLN. INFO.:				IL 1993-107268	A 19931012
				US 1994-321668	A3 19941012

IT **168042-60-2 168042-61-3 168042-62-4 168042-63-5 168042-64-6 168042-65-7 168042-66-8 168042-67-9 168042-68-0**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; mols. influencing shedding of tumor necrosis factor receptor, their prepn. with recombinant cells, and their pharmaceutical use)
IT **168042-49-7D**, Receptor, tumor necrosis factor (human), analogs
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; mols. influencing shedding of tumor necrosis factor receptor, their prepn. with recombinant cells, and their

pharmaceutical use)

L6 ANSWER 46 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:723253 CAPLUS
DOCUMENT NUMBER: 123:102775
TITLE: Glycophorin binding protein (GBP130) fusion
compositions
INVENTOR(S): Prendergast, Kenneth Francis
PATENT ASSIGNEE(S): UK
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9506737	A1	19950309	WO 1994-GB1900	19940901
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 716703	A1	19960619	EP 1994-924961	19940901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
PRIORITY APPLN. INFO.:			GB 1993-18350	19930903
			GB 1994-17021	19940823
			WO 1994-GB1900	19940901
IT 166025-12-3P 166025-13-4P 166025-14-5P				
166025-15-6P 166025-16-7P 166025-17-8P				
166025-18-9P 166025-19-0P 166025-20-3P 166025-21-4P				
166025-22-5P 166025-23-6P 166025-24-7P 166025-25-8P 166025-26-9P				
166025-27-0P 166025-28-1P 166025-29-2P 166025-30-5P 166025-31-6P				
166025-32-7P 166025-33-8P 166025-34-9P				
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (fusion protein contg. malaria parasite peptide capable of binding to red blood cell as therapeutic agent)				

L6 ANSWER 47 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:311914 CAPLUS
DOCUMENT NUMBER: 123:3721
TITLE: Amino acid sequence of natural tumor necrosis factor
.alpha. inhibitor purified from human urine
AUTHOR(S): Kajihara, Jun-ichi; Asada, Aki; Kirihara, Sei; Kato,
Kazuo
CORPORATE SOURCE: Biochemistry Res. Lab., JCR Pharmaceuticals Co.,
Ltd.,
Kobe, 651-22, Japan
SOURCE: Biosci., Biotechnol., Biochem. (1994), 58(12), 2266-8
CODEN: BBBIEJ; ISSN: 0916-8451
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 163611-40-3, Tumor necrosis factor .alpha. inhibitor
RL: PRP (Properties)
(amino acid sequence of tumor necrosis factor .alpha. inhibitor
purified from human urine)

L6 ANSWER 48 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:215346 CAPLUS
DOCUMENT NUMBER: 120:215346
TITLE: Modulation of the activity of the tumor necrosis
factor receptor
INVENTOR(S): Wallach, David; Brakebusch, Cord
PATENT ASSIGNEE(S): Yeda Research and Development Co., Ltd., Israel
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	EP 568925	A2	19931110	EP 1993-106981	19930429
	EP 568925	A3	19950315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 06233684	A2	19940823	JP 1993-138841	19930430
	US 6395267	B1	20020528	US 1993-54970	19930503
PRIORITY APPLN. INFO.:				IL 1992-101769	A 19920503
IT	129203-92-5D, p55 Tumor necrosis factor receptor (human), deletion and substitution derivs. RL: BIOL (Biological study) (altered signal transduction and cleavage properties of)				
IT	154102-45-1 154102-46-2 154102-47-3 154102-48-4 154102-49-5 154102-50-8 154102-51-9 154102-52-0 154102-53-1 RL: PRP (Properties) (amino acid sequence of, modulation of receptor activity in relation to)				

L6 ANSWER 49 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:189309 CAPLUS
DOCUMENT NUMBER: 120:189309
TITLE: A novel domain within the 55 kDa TNF receptor signals cell death
AUTHOR(S): Tartaglia, Louis A.; Ayres, T. Merrill; Wong, Grace H.
CORPORATE SOURCE: W.; Goeddel, David V.
Dep. Mol. Biol., Genentech, Inc., South San Francisco,
CA, 94080, USA
SOURCE: Cell (Cambridge, Mass.) (1993), 74(5), 845-53
CODEN: CELLB5; ISSN: 0092-8674
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 129876-53-5
RL: BIOL (Biological study)
(as tumor necrosis factor receptor p55, of humans, cytoplasmic domain of, in signal transduction of cytotoxicity)
IT 153640-99-4 153641-00-0 153641-01-1
153641-02-2 153641-03-3 153641-04-4
153641-05-5 153641-06-6 153641-07-7
153641-08-8 153641-09-9 153641-10-2
153641-11-3 153641-12-4 153641-13-5
153641-14-6 153641-15-7 153641-16-8
153641-17-9 153641-18-0 153641-19-1
153641-20-4 153641-21-5 153641-22-6
153641-23-7 153641-24-8 153641-25-9
RL: PRP (Properties)
(structure of, in human tumor necrosis factor receptor p55 signal transduction)

L6 ANSWER 50 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:70270 CAPLUS
DOCUMENT NUMBER: 120:70270
TITLE: Fusion proteins comprising human tumor necrosis factor receptor and human interleukin 1 receptor and their use in pharmaceuticals
INVENTOR(S): Smith, Craig A.
PATENT ASSIGNEE(S): Immunex Corp., USA
SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9319777	A1	19931014	WO 1993-US2938	19930326
W: AU, CA, FI, JP, KR, NO, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9339702	A1	19931108	AU 1993-39702	19930326
AU 671116	B2	19960815		
EP 670730	A1	19950913	EP 1993-909201	19930326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07508639	T2	19950928	JP 1993-517614	19930326
FI 9404516	A	19941122	FI 1994-4516	19940929
NO 9403617	A	19941129	NO 1994-3617	19940929
PRIORITY APPLN. INFO.:			US 1992-860710	19920330
			WO 1993-US2938	19930326
IT 124541-29-3, Type I interleukin-1 receptor (human) 129203-92-5, Tumor necrosis factor receptor (human) 134773-87-8, Tumor necrosis factor receptor (human) 134773-89-0, [-22-142]Sol. tumor necrosis factor receptor (human) 134773-90-3, [-22-163]Sol. tumor necrosis factor receptor (human) 134773-91-4, [-22-185]Sol. tumor necrosis factor receptor (human) 134773-92-5, [-22-235]Sol. tumor necrosis factor receptor (human) 142106-89-6, Type II interleukin-1 receptor (human) 142106-95-4, [-13-333]Type II interleukin-1 receptor (human) RL: PRP (Properties) (amino acid sequence of)				

L6 ANSWER 51 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:206344 CAPLUS
DOCUMENT NUMBER: 118:206344
TITLE: Structure of the human TNF receptor 1 (p60) gene
(TNRF1) and localization to chromosome 12p13
AUTHOR(S): Fuchs, Peter; Strehl, Sabine; Dworzak, Michael;
Himmeler, Adolf; Ambros, Peter F.
CORPORATE SOURCE: Dep. Mol. Biol., Ernst Boehringer Inst., Vienna,
A-1121, Austria
SOURCE: Genomics (1992), 13(1), 219-24
CODEN: GNMCEP; ISSN: 0888-7543
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 129203-92-5P
RL: PREP (Preparation)
(prepn. of)

L6 ANSWER 52 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:154551 CAPLUS
DOCUMENT NUMBER: 118:154551
TITLE: Polypeptide conjugates for therapeutics
INVENTOR(S): Thompson, Robert C.; Armes, Lyman G.; Evans, Ronald
J.; Brewer, Michael T.; Kohno, Tadahiko
PATENT ASSIGNEE(S): Synergen, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9216221 A1 19921001 WO 1992-US2122 19920313
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP,
KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN,
GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG
CA 2106079 AA 19920916 CA 1992-2106079 19920313
AU 9216742 A1 19921021 AU 1992-16742 19920313
EP 575545 A1 19931229 EP 1992-909329 19920313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE
JP 06506218 T2 19940714 JP 1992-508915 19920313
RU 2148586 C1 20000510 RU 1993-58326 19920313
NO 9303270 A 19931101 NO 1993-3270 19930914
AU 9662023 A1 19961031 AU 1996-62023 19960809
AU 708533 B2 19990805
PRIORITY APPLN. INFO.: US 1991-669862 A 19910315
US 1992-822296 A 19920117
WO 1992-US2122 A 19920313
IT **133723-60-1DP**, conjugates with polyethylene glycol derivs.
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and bioactivity of, for therapeutic, prolonged i.v. mean
residence time in relation to)

L6 ANSWER 53 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:549300 CAPLUS
DOCUMENT NUMBER: 117:149300
TITLE: Tumor necrosis factor .alpha. receptor derivatives
lacking an extracellular subdomain
INVENTOR(S): Feldmann, Marc; Gray, Patrick William; Turner, Martin
John Charles; Brennan, Fionula Mary
PATENT ASSIGNEE(S): Charing Cross Sunley Research Centre, UK
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9207076	A1	19920430	WO 1991-GB1826	19911018
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
EP 556207	A1	19930825	EP 1991-918343	19911018
EP 556207	B1	19980812		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06504192	T2	19940519	JP 1991-516906	19911018
AT 169675	E	19980815	AT 1991-918343	19911018
ES 2121789	T3	19981216	ES 1991-918343	19911018
US 5633145	A	19970527	US 1993-50319	19930510
US 5863786	A	19990126	US 1995-465982	19950606
PRIORITY APPLN. INFO.:			GB 1990-22648	19901018
			WO 1991-GB1826	19911018
			US 1993-50319	19930510

IT **132966-32-6 132966-33-7**
RL: PRP (Properties)
(amino acid sequence of, complete, and cloning and expression and
mutagenesis of cDNA for)
IT **143638-87-3 143638-89-5 143638-91-9**
143638-93-1
RL: PRP (Properties)
(amino acid sequence of, complete, and expression in COS cells of cDNA
for, inhibition of tumor necrosis factor .alpha. activity in relation
to)
IT **143638-83-9**
RL: PRP (Properties)
(amino acid sequence of, complete, inhibition of tumor necrosis factor

.alpha. activity by)

L6 ANSWER 54 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:488638 CAPLUS
DOCUMENT NUMBER: 117:88638
TITLE: Tumor necrosis factor-.alpha. (TNF.alpha.)-binding
protein.
INVENTOR(S): Feldmann, Marc; Gray, Patrick; Turner, Martin;
Brennan, Fionula
PATENT ASSIGNEE(S): Charing Cross Sunley Research Centre, UK
SOURCE: Brit. UK Pat. Appl., 25 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	GB 2246569	A1	19920205	GB 1990-13410	19900615
IT	132966-32-6				
	RL: BIOL (Biological study) (amino acid sequence of and cloning of cDNA for)				
IT	142804-97-5				
	RL: BIOL (Biological study) (amino acid sequence of and cloning of cDNA for and therapy with)				

L6 ANSWER 55 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:529141 CAPLUS
DOCUMENT NUMBER: 115:129141
TITLE: Cloning and expression of tumor necrosis factor
receptor and soluble binding protein cDNAs
INVENTOR(S): Wallach, David; Nophar, Yaron; Kemper, Oliver;
Engelmann, Hartmut; Brakebusch, Cord; Aderka, Dan
PATENT ASSIGNEE(S): Yeda Research and Development Co., Ltd., Israel
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	EP 433900	A1	19910626	EP 1990-124133	19901213
	EP 433900	B1	19950920		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 92697	A1	19960331	IL 1989-92697	19891213
	CA 2032191	AA	19910614	CA 1990-2032191	19901213
	AU 9068037	A1	19910620	AU 1990-68037	19901213
	AU 642938	B2	19931104		
	ZA 9010036	A	19911030	ZA 1990-10036	19901213
	JP 05078396	A2	19930330	JP 1990-419240	19901213
	AT 128184	E	19951015	AT 1990-124133	19901213
	ES 2080098	T3	19960201	ES 1990-124133	19901213
	JP 04299989	A2	19921023	JP 1990-419119	19901226
	US 5811261	A	19980922	US 1993-126016	19930924
PRIORITY APPLN. INFO.:				IL 1989-92697	A 19891213
				IL 1990-95064	A 19900712
				US 1988-243092	B2 19880912
				US 1990-625668	B1 19901213
IT	129203-92-5 133723-58-7				
	RL: PRP (Properties) (amino acid sequence of and cloning in Escherichia coli and expression in animal cell culture of cDNA for)				
IT	135945-36-7				

RL: PRP (Properties)
(amino acid sequence of and expression in CHO cells of cDNA for)

L6 ANSWER 56 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:529124 CAPLUS

DOCUMENT NUMBER: 115:129124

TITLE: Tumor necrosis factor inhibitor, its purification and recombinant manufacture

INVENTOR(S): Brewer, Michael T.; Hale, Karin K.; King, Michael W.; Kohno, Tadahiko; Squires, Charles; Thompson, Robert C.; Vanderslice, Rebecca W.; Vannice, James

PATENT ASSIGNEE(S): Synergen, Inc., USA

SOURCE: Can. Pat. Appl., 129 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2021369	AA	19910119	CA 1990-2021369	19900717
AU 9058976	A1	19910124	AU 1990-58976	19900716
AU 647397	B2	19940324		
NO 9003192	A	19910121	NO 1990-3192	19900717
EP 422339	A1	19910417	EP 1990-113673	19900717
EP 422339	B1	19980128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DD 296963	A5	19911219	DD 1990-342854	19900717
ZA 9005593	A	19920226	ZA 1990-5593	19900717
PL 168844	B1	19960430	PL 1990-286089	19900717
EP 790306	A2	19970820	EP 1997-103361	19900717
EP 790306	A3	19980701		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 162801	E	19980215	AT 1990-113673	19900717
ES 2116970	T3	19980801	ES 1990-113673	19900717
JP 03163099	A2	19910715	JP 1990-190372	19900718
US 6143866	A	20001107	US 1995-375242	19950119
PRIORITY APPLN. INFO.:			US 1989-381080	A 19890718
			US 1989-450329	A 19891211
			US 1990-479661	A 19900207
			EP 1990-113673	A3 19900717
			US 1990-555274	B1 19900719
			US 1993-90366	B1 19930709

IT 133723-60-1 135686-05-4 135686-06-5

RL: PRP (Properties); BIOL (Biological study)

(amino acid sequence of and expression in Escherichia coli of cDNA for)

L6 ANSWER 57 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:466200 CAPLUS

DOCUMENT NUMBER: 115:66200

TITLE: Tnf(Tumor necrosis factor)-binding proteins and cloning and expression of cDNAs encoding them

INVENTOR(S): Brockhaus, Manfred; Dembic, Zlatko; Gentz, Reiner; Lesslauer, Werner; Loetscher, Hansruedi; Schlaeger, Ernst Juergen

PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.

SOURCE: Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

EP 417563	A2	19910320	EP 1990-116707	19900831
EP 417563	A3	19920429		
EP 417563	B1	20000705		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, NL				
EP 939121	A2	19990901	EP 1999-100703	19900831
EP 939121	A3	19991124		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, NL				
AT 194384	E	20000715	AT 1990-116707	19900831
EP 1132471	A2	20010912	EP 2001-108117	19900831
EP 1132471	A3	20011128		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, NL				
JP 04164099	A2	19920609	JP 1990-240176	19900912
JP 2728968	B2	19980318		
JP 10095800	A2	19980414	JP 1997-257433	19900912
JP 10114795	A2	19980506	JP 1997-257432	19900912
US 5610279	A	19970311	US 1993-95640	19930721
US 5808029	A	19980915	US 1995-444793	19950519
PRIORITY APPLN. INFO.:			CH 1989-3319	A 19890912
			CH 1990-746	A 19900308
			CH 1990-1347	A 19900420
			EP 1990-116707	A3 19900831
			EP 1999-100703	A3 19900831
			US 1990-580013	B1 19900910
			JP 1990-240176	A3 19900912
			US 1993-95640	A3 19930721
IT	129203-92-5 129876-53-5 135114-77-1			
	RL: PRP (Properties)			
	(amino acid sequence of and cloning and expression in animal cells of cDNA for)			
IT	134562-25-7	134562-26-8	134562-27-9	134562-28-0
	134562-29-1	134562-30-4	134562-31-5	134562-32-6
	RL: PRP (Properties)			
	(tumor necrosis factor binding protein peptide, of HL-60 cells, cDNA cloning in relation to)			
L6 ANSWER 58 OF 64 CAPLUS COPYRIGHT 2002 ACS				
ACCESSION NUMBER:		1991:465733 CAPLUS		
DOCUMENT NUMBER:		115:65733		
TITLE:		Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein		
AUTHOR(S):		Himmler, Adolf; Maurer-Fogy, Ingrid; Kroenke, Martin; Scheurich, Peter; Pfizenmaier, Klaus; Lantz, Mikael; Olsson, Inge; Hauptmann, Rudolf; Stratowa, Christian; Adolf, Guenther R.		
CORPORATE SOURCE:		Ernst Boehringer Inst., Bender and Co. G.m.b.H., Vienna, 1121, Austria		
SOURCE:		DNA Cell Biol. (1990), 9(10), 705-15		
		CODEN: DCEBE8; ISSN: 1044-5498		
DOCUMENT TYPE:		Journal		
LANGUAGE:		English		
IT	133723-60-1 135114-98-6 135114-99-7			
	135115-00-3	135115-01-4	135115-02-5	
	RL: PRP (Properties)			
	(amino acid sequence of)			
L6 ANSWER 59 OF 64 CAPLUS COPYRIGHT 2002 ACS				
ACCESSION NUMBER:		1991:222818 CAPLUS		
DOCUMENT NUMBER:		114:222818		
TITLE:		Cloning and expression of a cDNA for tumor necrosis factor receptor		
INVENTOR(S):		Hauptmann, Rudolf; Himmler, Adolf; Maurer-Fogy, Ingrid; Stratowa, Christian		
PATENT ASSIGNEE(S):		Boehringer Ingelheim International G.m.b.H., Fed. Rep.		

SOURCE: Ger.
Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393438	A2	19901024	EP 1990-106624	19900406
EP 393438	A3	19910619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3913101	A1	19901031	DE 1989-3913101	19890421
DE 3920282	A1	19910103	DE 1989-3920282	19890621
JP 03164179	A2	19910716	JP 1990-105102	19900420
US 6294352	B1	20010925	US 1995-383676	19950201
US 5843791	A	19981201	US 1995-477639	19950607
US 6221675	B1	20010424		
US 6271346	B1	20010807	US 1995-484312	19950607
US 6417158	B1	20020709	US 1995-477638	19950607
US 2002090676	A1	20020711	US 2001-899422	20010703
PRIORITY APPLN. INFO.:				
			DE 1989-3913101	A 19890421
			DE 1989-3920282	A 19890621
			EP 1990-106624	A 19900406
			US 1990-511430	B3 19900420
			US 1992-821750	B1 19920102
			US 1993-153287	B1 19931117
			US 1995-383676	A3 19950201
			US 2000-525998	A3 20000315

IT 129203-92-5 133723-60-1

RL: PRP (Properties)

(amino acid sequence of and cloning in Escherichia coli and expression in COS-7 cells of cDNA for)

L6 ANSWER 60 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:200676 CAPLUS

DOCUMENT NUMBER: 114:200676

TITLE: Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned

using

amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor

AUTHOR(S): Nophar, Yaron; Kemper, Oliver; Brakebusch, Cord; Engelmann, Hartmut; Zwang, Raya; Aderka, Dan; Holtmann, Helmut; Wallach, David

CORPORATE SOURCE: Dep. Mol. Genet. Virol., Weizmann Inst. Sci., Rehovot,

SOURCE: 76100, Israel
EMBO J. (1990), 9(10), 3269-78
CODEN: EMJODG; ISSN: 0261-4189

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 129203-92-5 133723-58-7

RL: PRP (Properties)

(amino acid sequence of)

L6 ANSWER 61 OF 64 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:158076 CAPLUS

DOCUMENT NUMBER: 114:158076

TITLE: Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble

TNF-binding

protein

AUTHOR(S): Gray, Patrick W.; Barrett, Kathy; Chantry, David;

CORPORATE SOURCE: Turner, Martin; Feldmann, Marc
Charing Cross Sunley Res. Cent., Hammersmith/London,
W6 8LW, UK
SOURCE: Proc. Natl. Acad. Sci. U. S. A. (1990), 87(19),
7380-4
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 132966-32-6 132966-33-7
RL: PRP (Properties)
(amino acid sequence of)

L6 ANSWER 62 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:566404 CAPLUS
DOCUMENT NUMBER: 113:166404
TITLE: Molecular cloning and expression of the human 55 kd
tumor necrosis factor receptor
AUTHOR(S): Loetscher, Hansruedi; Pan, Yu Ching E.; Lahm, Hans
Werner; Gentz, Reiner; Brockhaus, Manfred; Tabuchi,
Hisahiro; Lesslauer, Werner
CORPORATE SOURCE: Cent. Res. Units, F. Hoffmann-LaRoche Ltd., Basel,
4002, Switz.
SOURCE: Cell (Cambridge, Mass.) (1990), 61(2), 351-9
CODEN: CELLB5; ISSN: 0092-8674
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 129203-92-5 129876-53-5
RL: PRP (Properties)
(amino acid sequence of)

L6 ANSWER 63 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:510208 CAPLUS
DOCUMENT NUMBER: 113:110208
TITLE: Molecular cloning and expression of a receptor for
human tumor necrosis factor
AUTHOR(S): Schall, Thomas J.; Lewis, Martyn; Koller, Kerry J.;
Lee, Angela; Rice, Glenn C.; Wong, Grace H. W.;
Gatanaga, Tetsuya; Granger, Gale A.; Lentz, Rigdon;
et
al.
CORPORATE SOURCE: Dep. Mol. Biol., Genentech, Inc., South San
Francisco,
CA, 94080, USA
SOURCE: Cell (Cambridge, Mass.) (1990), 61(2), 361-70
CODEN: CELLB5; ISSN: 0092-8674
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 129203-92-5 129203-93-6
RL: PRP (Properties)
(amino acid sequence of)

L6 ANSWER 64 OF 64 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:438760 CAPLUS
DOCUMENT NUMBER: 113:38760
TITLE: Purification and characterization of human tumor
necrosis factor .alpha. inhibitor
INVENTOR(S): Dayer, Jean Michel; Seckinger, Philippe Lucien
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

DE 3910323	A1	19891019	DE 1989-3910323	19890330
DK 8901565	A	19891001	DK 1989-1565	19890330
SE 8901115	A	19891001	SE 1989-1115	19890330
AU 8932287	A1	19891005	AU 1989-32287	19890330
FR 2629345	A1	19891006	FR 1989-4160	19890330
NL 8900779	A	19891016	NL 1989-779	19890330
GB 2218101	A1	19891108	GB 1989-7148	19890330
BE 1001845	A4	19900320	BE 1989-350	19890330
JP 02117700	A2	19900502	JP 1989-76871	19890330
PRIORITY APPLN. INFO.:			GB 1988-7803	19880331
IT 128074-52-2				
RL: PRP (Properties)				
(amino acid sequence of)				

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	93.38	200.73

STN INTERNATIONAL LOGOFF AT 10:25:43 ON 31 JUL 2002